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Abstract
In 2008, the National Institutes of Health (NIH) mandated that the full text of NIH-
supported articles be made freely available on PubMed Central (PMC) – the NIH’s repository
of biomedical research. This paper uses ∼ 1 million NIH articles and several matched com-
parison samples to examine how this “PMC mandate” impacted researcher access to the
biomedical literature and publishing patterns in biomedicine. Estimates of the mandate’s
impact on forward citations to NIH articles tend to be noisy and inconsistent across samples,
models, and specifications, and the largest upper limits of confidence intervals cannot rule
out substantial increases. However, the most credible estimates suggest that the mandate
had a relatively modest effect on citations, which is consistent with most researchers having
widespread access to the biomedical literature prior to the mandate, leaving little room for
the mandate to increase access. I also find that NIH articles are more likely to be published
in traditional subscription-based journals (as opposed to “open access” journals) after the
mandate. This indicates that any discrimination the mandate induced, by subscription-
based journals against NIH articles, was offset by other factors – possibly the decisions of
editors and submission behavior of authors.
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tion.
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1 Introduction
Economists have long argued that scientific advancement is crucial for economic growth.
Since science is a cumulative process (Aghion et al., 2008; Aghion and Howitt, 1992; Mokyr,
2002; Murray et al., 2009; Romer, 1990; Scotchmer, 1991), its advancement depends on re-
searchers having broad access to the scientific literature. This insight has facilitated the
increasingly common practice, by departments, universities, and funding agencies, of man-
dating that affiliated scientific articles be made open access – “digital, online, free of charge,
and free of most copyright and licensing restrictions” (Suber, 2012, p. 4).1 In keeping with
this trend, the National Institutes of Health (NIH) implemented a mandate in 2008, which
stipulates that, regardless of where it is published, any NIH-funded article must be submitted
to PubMed Central (PMC) – the NIH’s repository of biomedical research (and the most com-
monly used such repository). The full text of the final peer-reviewed version of the article is
then made freely available on PMC within 12 months of publication.2 This paper examines
how the NIH’s “PMC mandate” impacted researcher access to the biomedical literature as
well as how it impacted publishing patterns in biomedicine.
Promoting scientific advancement by increasing access to the biomedical literature was
an important concern underpinning the implementation of the PMC mandate.3 At the time,
most empirical work indicated that open access articles receive substantially more citations
than non-open access articles. Using a sample of computer science articles, Lawrence (2001)
found that articles freely available online receive 336% more citations than those not available
online. Using a sample of physics and mathematics articles, Harnad and Brody (2004) found
that articles freely available in arXiv (a large repository of freely downloadable scientific
articles) receive 298% more citations than those not in arXiv. Similarly, Metcalfe (2005),
Metcalfe (2006), and Davis and Fromerth (2007) found that astrophysics, solar physics, and
mathematics articles posted on arXiv receive about 100%, 260%, and 35% more citations
1See the Registry of Open Access Repositories Mandatory Archiving Policies (ROARMAP) for a list of
open access mandates.
2Note that the PMC mandate does not require NIH-funded articles to be published in an open access
journal such as those in the BioMed Central (BMC) or Public Library of Science (PLOS) portfolios. Nor
does it require authors to use grant funds to purchase open access status for their NIH-funded article in an
otherwise subscription-based journal (most publishers allow authors to pay article processing charges (APCs)
to make an article open access). The PMC mandate simply requires that, no matter where an NIH article is
published, the post-refereed (but possibly pre-print) version of the article must also be submitted to PubMed
Central (PMC), where it will be made fully and freely available to anyone with an internet connection.
3In testimony to the House Judiciary Committee, then NIH Director Elias Zerhouni stated: “The policy
has two basic premises: 1) the integration and accessibility of biomedical research will speed discoveries
(my emphasis), resulting in the prevention of death and and disability; and 2) the public has a right to
have full access, without charge, to research findings supported by taxpayer dollars, after a reasonable
period of embargo (p. 26).” See https://judiciary.house.gov/hearing/hearing-on-h-r-6845-the-fair-copyright-
in-research-works-act-0/
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than articles not posted. Antelman (2004) found that articles in philosophy, political science,
electrical and electronic engineering, and mathematics receive 45%, 86%, 51%, and 91%
more citations when they are freely available online. Walker (2004) examined articles in
an oceanography journal, and found that articles whose authors paid to have them freely
available received 280% more downloads. Craig et al. (2007) provide a useful review of this
early literature.
These results suggested that restrictions on researcher access to the scientific literature
had bite, potentially hindering scientific progress. This paper leverages the PMC mandate
as a natural experiment to examine whether open access increases researcher access to the
biomedical literature. If, prior to the mandate, some researchers had difficulty accessing NIH
articles, then, after the mandate, we should observe an increase in the rate at which NIH
articles are cited in follow-on research. In particular, there should be an increase in citations
to NIH articles published in traditional subscription-based (toll access) journals, which prior
to the mandate (and unlike NIH articles published in open access journals), would have been
unavailable to researchers without a subscription to the journal.
I identify the effect of the PMC mandate on researcher access by using (∼ 1 million) NIH-
funded articles combined with several sets of comparison articles to estimate difference-in-
differences models, which allow me to examine how citations to NIH articles changed after the
mandate was implemented in 2008. The main estimates vary widely across samples, models,
and specifications, so I focus on confidence intervals, which allow me to examine what effects
can be ruled out with statistical confidence and to bound the plausible increase in citations
caused by the mandate. This approach suggests that, while the maximum upper limit on
the entire set of 95% confidence intervals (CIs) cannot rule out large increases in citations
after implementation of the PMC mandate (up to 46.8%), more credible upper confidence
limit estimates suggest a much more modest upper bound on this increase (a bit less than
8%).4 Thus, even the largest upper confidence limit estimates are smaller than the point
estimates found in most early work examining the impact of open access on citations. By
way of comparison, most of my point estimates are small and statistically indistinguishable
from zero, and several are actually negative. My largest point estimate implies that the PMC
mandate increased citations by 22.4% (statistically insignificant) with more credible point
estimates suggesting an increase of no more than of 3.7%. The more credible estimates are
4I extensively probe the robustness of the main results – that is, a likely modest, but possibly large, effect
of the PMC mandate on citations to NIH articles. The results are robust to different ways of estimating
standard errors, alternate outcome variables used to measure researcher access to the biomedical literature,
and functional form assumptions. The results are also robust to using a sub-sample of the data that eliminates
comparison articles subject to an open access mandate other than the PMC mandate. Finally, I examine
whether the PMC mandate differentially impacted articles supported through the NIH’s intramural research
program relative to articles supported extramurally through grants.
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consistent with recent work, which takes seriously the endogeneity of open access, showing
that, in contrast to earlier work, making articles open access does not substantially increase
citations to those articles (Evans and Reimer, 2009; McCabe and Snyder, 2014; Gaule and
Maystre, 2011; Davis et al., 2008; Davis, 2011b; Bryan and Ozcan, 2016; Kim, 2012). That
said, from the perspective of policymakers, a probable modest upper bound combined with
a possible large upper bound, may be enough to justify the implementation of the PMC
mandate. Moreover, it is important to note that these results do not indicate whether
the mandate increased access for doctors, inventors, or other consumers of the biomedical
literature.5
Most work on the relationship between open access and citations has used samples domi-
nated by researchers affiliated with universities or research hospitals in rich countries. These
researchers’ access to the entire biomedical literature may explain why the increase in total
citations tends to be modest when an article becomes open access. In contrast, researchers
in poor countries or at commercial enterprises (especially start-ups) may have more limited
access to the biomedical literature in the absence of the mandate (Ware and Monkman,
2009; Houghton et al., 2011), and thus may disproportionately benefit from NIH articles be-
coming freely available on PubMed Central. To examine this possibility, I also estimate how
citations from researchers in poor/developing countries and from researchers at commercial
enterprises are impacted by the PMC mandate.
Again focusing on confidence intervals, the largest upper limits do not rule out substan-
tial increases in citations – up to 62.8% from researchers at commercial enterprises and up
to 49.5% from researchers in poor/developing countries. However, more credible estimates
again suggest more modest upper bounds – a 9.6% increase for citations from researchers
at commercial enterprises and a still large 18.0% increase for citations from researchers in
poor/developing countries. Even these upper confidence limit estimates are smaller than
most point estimates found in the early literature examining the effect of open access on
citations. As with my point estimates of the PMC mandate’s impact on total citations, my
point estimates for citations from researchers in poor/developing countries and at commer-
cial enterprises vary widely across samples, models, and specifications. Overall, the point
estimates for both groups tend to be small, are often statistically insignificant, and are some-
times negative. The more credible point estimates suggest that the PMC mandate increased
citations by no more than 4.3% from researchers at commercial enterprises and by no more
than 6.5% from researchers in poor/developing countries. To my knowledge, Davis (2011a),
5Bryan and Ozcan (2016) find that the PMC mandate increased patent-to-article citations by 25 to 51
percent. Teplitskiy et al. (2017) estimate that the odds an open access journal is referenced on Wikipedia
(English version) are 47% higher compared to toll access journals.
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Evans and Reimer (2009), Faber Frandsen (2009), and Gaule´ (2009) have examined the im-
pact of open access on citations from poor countries and no one has examined the impact
on citations from commercial enterprises.
Given the non-rivalrous nature of ideas, ideas’ importance for economic growth, and the
cumulative nature of science, it is crucial to understand the impacts of restrictions (and the
lifting of restrictions) on access to scientific research. This is especially true for biomedical
research, which is estimated to yield large returns (Murphy and Topel, 2003). By analyzing
how the abolition of a particular set of restrictions (the PMC mandate) impacts access to
the biomedical literature, this paper fits into an “open science” literature that examines
the extent to which restrictions on access to scientific literature and materials can impede
scientific progress (Furman and Stern, 2011; Murray et al., 2009; Sampat and Williams, 2015;
Williams, 2013).
Though not as widely discussed as researcher access, another potential impact of the PMC
mandate is the alteration of publication patterns in the biomedical sciences. In particular, the
mandate may have induced toll access journals to discriminate, at the margin, against NIH
articles. From a journal’s point-of-view, making NIH articles freely available on PubMed
Central risks reducing subscription revenue. For this reason, prominent publishers of toll
access journals strongly opposed the PMC mandate.6 However, a couple factors may work
to attenuate discrimination. First, if journal editors are only concerned with an article’s
scientific merit, and do not take the publisher’s revenue into account when making decisions,
then journal discrimination against NIH articles may be reduced. Second, authors can also
influence the distribution of articles across toll and open access journals by deciding where
to submit their work. To the extent that authors value “open science”, the PMC mandate
reduces one of the main costs of publishing an NIH article in a toll access journal – restricted
6Indeed, the Association of American Publishers, which represents all major publishers in biomedicine,
specifically warned that the PMC mandate would undermine its members’ economic incentives by making
their content available online (www.publishers.org/issues/5/9). For news accounts of debate surrounding
the mandate and publishers’ opposition, see Weiss (2007), Giles (2007), and English and Joseph (2008).
One member of the publishing industry explicitly suggested that “Another possible implication [of the PMC
mandate] is that journals may no longer be willing to review and accept articles with unsustainable terms
attached” (McMullan, 2008). Moreover, the publishing industry strongly backed the Fair Copyright in
Research Works Act (introduced in 2008 and 2009) and the Research Works Act (introduced in 2011), which
aimed to repeal the PMC mandate. There are a few strands of additional evidence suggesting that the PMC
mandate may have induced journals to discriminate against NIH articles. Seamans (2001) found that, in a
sample of mostly non-profit journals, 17.64 percent expressed reservations about accepting submissions of
theses and dissertations available on the web. Howard (2011) documents several university press editors’
reluctance to publish theses and dissertations that can be found “immediately on Google or by going to the
university page and just clicking and downloading it...”. Finally, as noted by (Suber, 2012, p. 173), medicine
is a field particularly likely to follow the “Ingelfinger Rule” and refuse to accept articles that have circulated
online. Thus it is reasonable to suspect that the PMC mandate may have made toll access journals less
inclined, at the margin, to publish NIH articles.
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access – by ensuring that these articles are freely available on PubMed Central. Several
studies using surveys and interviews, suggest that at least some authors do, in fact, value
open science.7 Moreover, prior to the mandate, NIH-funded authors – either because they
value open science or because they want to maximize their articles’ exposure – may have
been more willing to use scarce grant dollars to pay the submission or publication fees that
are typically required to publish in open access journals.8 Without paying such fees, their
articles would exist indefinitely behind a paywall. In contrast, after the mandate, authors
know that, regardless of whether an article is published in an open or toll access journal, it
will be made freely available on PubMed Central. Thus, some NIH-funded authors may have
been less inclined to pay open access fees and instead opted to submit their NIH articles to
toll access journals, which typically charge more modest submission fees.
From a policy perspective, the NIH aims to fund lines of research with the highest overall
merit and impact (see reviewer criteria). If the PMC mandate induces discrimination, by
toll access journals against NIH articles, this reduces the number of outlets available to NIH
articles, possibly decreasing the flow of follow-on research and hindering the advancement
of the very research lines the NIH deems most crucial to promote. Thus, it is imperative to
understand whether the net impact of the PMC mandate was dominated by discrimination
against NIH articles or if mitigating factors such as editor/author decisions attenuated such
discrimination.
I use several samples of NIH and comparison articles combined with difference-in-
differences models to examine the net effect of the PMC mandate on publishing patterns in
biomedcine. Specifically, I examine the impact of the mandate on the probability that an
article is published in a traditional toll access journal. Across most samples, models, and
specifications, the effect of the PMC mandate is precisely estimated and suggests an increase,
of up to 2%, in the probability that an NIH article is published in a toll access journal. From
a policy perspective, these results suggest that a significant potential downside of the PMC
7When asked about their reasons for publishing in open access journals, Swan and Brown (2004) find
that authors’ most common response (92%) is the “principle of free access for all readers”. Further, when
asked if they would have published in the same journal had it been toll access, nearly half said they would
not and another third said they did not know. After interviewing 14 biomedical faculty from UNC-Chapel
Hill and Duke, Warlick and Vaughan (2007) report that 9 view open access as an important part of deciding
where to publish and 2 say it is increasingly important. Moreover, 9 say that “free access” is the most
important motivation for publishing in an open access journal. In addition, nearly 17,000 (as of March 2018)
researchers have signed their name to the “Cost of Knowledge” protest, pledging to refrain from publishing
in or providing referee/editorial work for Elsevier journals. One of the main reasons for this protest is the
perception that Elsevier restricts open access. See: http://thecostofknowledge.com/
8The NIH has always allowed publication and printing costs to be charged to grants. Sec-
tion 7.9 of the NIH Grants Policy Statement states that, “Publication costs for electronic
and print media, including distribution, promotion, and general handling are allowable.” See:
https://grants.nih.gov/grants/policy/nihgps/html5/section 7/7.9 allowability of cos.
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mandate – discrimination against NIH articles – was either unrealized or attenuated by other
factors, such as the decisions of editors and authors.9
Moving forward, the paper is organized as follows. Section 2 describes the data. Section
3 discusses the details of the PMC mandate and my econometric strategy. Section 4 presents
the results, and Section 5 concludes.
2 Data
The data used in this paper are obtained from three main sources: MEDLINE, Web of Science
(WOS), and the Directory of Open Access Journals (DOAJ). MEDLINE is a bibliographic
database maintained by the National Library of Medicine and is the most comprehensive
index of the biomedical literature.10 It includes a variety of information about each indexed
article, including the year and journal in which it is published and any grants that support
it (in particular, NIH grants). WOS is maintained by Clarivate Analytics and indexes the
references of journals across all fields (including those in MEDLINE).11 It enables the tracking
of citation relationships between MEDLINE articles. DOAJ is the most comprehensive index
of open access journals across all fields, and it enables the labeling of journals in MEDLINE
as open or toll access. For more details on all data, see Appendix A.
2.1 Outcome Variables
The first set of outcomes are designed to measure whether the PMC mandate increased
access to the biomedical literature. I first examine the total number of 2-year forward
citations that an article receives. Next, I examine the number of 2-year forward citations
that an article receives from particular subsets of authors. Specifically, I restrict the count of
2-year forward citations to those from authors at commercial enterprises and to those from
9Ideally, I would use submission data in addition to publication data to study the effects of author/editor
behavior. Such data would allow me to directly examine whether rates of submission, by authors, of NIH
articles to different journal types changed after the mandate. Similarly, I would be able to examine whether
rates of acceptance, by editors, of NIH articles at different journal types changed. Unfortunately, I am not
aware of any publicly available source of submission data.
10Technically, MEDLINE is a subset of a larger database called PubMed (distinct from PubMed Central).
However, the data in MEDLINE have undergone rigorous quality control and are readily available for use
by researchers.
11The other two main sources of citation data are Scopus (Elsevier) and Google Scholar. Like WOS,
Scopus is proprietary and identifies citations using lists of journals. In contrast, Google Scholar crawls the
web looking for citations. Though Google Scholar tends to be more comprehensive than either WOS or
Scopus, it does not allow bulk data access. Fortunately, the overlap between the three sources of data is
substantial and the correlations between citations from the three sources are close to 1 – especially in Health
and Medical Sciences. See Mart´ın-Mart´ın et al. (2018) for an overview of these three sources of citation data
and comparisons between them.
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authors at institutions located in poor or developing countries.12 Since the WOS citation
data end in mid-2014, I end the analysis for 2-year forward citation measures in 2011, which
ensures that all articles have a full 2 years to accrue citations.13 In Section 4.2, I probe the
robustness of the main results by estimating models that use all citations ever received as the
outcome variable, which allows for an analysis of the PMC mandate’s longer run impact on
citations. In addition, I estimate models that use, as outcomes, dummy variables indicating
whether an article receives any citations within two years of publication and whether an
article receives a citation any time after publication.
The second set of outcomes are designed to measure how the PMC mandate impacted
publishing patterns in biomedicine – specifically, whether an article is published in an open
access or toll access journal. The primary way a journal is identified as open access is if it is
indexed by the Directory of Open Access Journals (DOAJ). If it is not indexed in DOAJ, it is
classified as toll access.14 To probe the quality of this open access indicator, I also construct
an alternative measure using the PubMed Central Open Access Subset (PMC-OAS) – the
set of open access articles in PubMed Central. The fraction of articles that do not belong to
the PMC-OAS (that is, are toll access) is computed for each journal. This fraction, is used
as an alternative outcome measuring a journal’s openness.
2.2 NIH Articles and Comparison Articles
There are 2,050,044 articles in MEDLINE tagged as being funded by the National Institutes
of Health (NIH). 956,801 of these are published between 2003 and 2013 (the time frame for
the analysis of publishing patterns) and 745,076 between 2003 and 2011 (the time frame for
12I identify articles affiliated with a commercial enterprise using MapAffil (Torvik, 2015) and articles
from poor/developing countries using a combination of MapAffil and the United Nations National Accounts.
MapAffil uses author affiliations in MEDLINE to assign, to each MEDLINE article, information on location
and organization type. Unfortunately, until 2014, only the affiliation of the first author was recorded in
MEDLINE. Thus, for my time period (2003-2013), an article can only be assigned as having been produced
by an author at a commercial organization or in a poor/developing country on the basis of the first author’s
affiliation information. See Appendix A for details.
13The WOS citation data end in mid-2014 because this was the time period the data were extracted from
the WOS database (by WOS staff) and transferred for research purposes under NIH Grant P01 AG039347.
14For several reasons, this classification scheme is imperfect. First, some journals in MEDLINE may be
open access, but are not indexed in DOAJ. Such journals will be falsely classified as toll access. Second,
a journal may be open access (or toll access) at one point in time, and then change status. Such journals
will be correctly classified in some years and falsely classified in others. Third, some journals are neither
fully open nor fully toll access. For instance, some journals allow authors to pay a fee to make their article
open access in an otherwise toll access journal. Other journals allow some forms of “green” open access,
which allow researchers to put non-final versions of their articles on personal webpages or repositories like
PubMed Central. Still other journals embargo articles for a time and then open them to all researchers.
Unfortunately, the DOAJ data do not allow me to address these nuances. However, note that the PMC-OAS
measure does help address the first three issues.
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the analysis of researcher access).
To pin down counterfactual outcomes, I construct several sets of comparison articles
using non-NIH articles. The first comparison sample is the set of all non-NIH articles in
MEDLINE published between 2003 and 2013 (2011). There are 7,482,563 (5,809,078) such
articles. I refer to this set of comparison articles as the “MEDLINE” comparison sample.
The second set of comparison articles is the set of all non-NIH articles published in the same
journal and year as at least one NIH article.15 There are 5,792,555 (4,455,039) such articles.
I refer to this set of comparison articles as the “Journal” sample.
The third set of comparison articles is constructed using the PubMed Related Citations
Algorithm (PRCA), which uses key words (MeSH terms) and text from titles and abstracts,
to identify, for any given article, a set of “similar” articles.16 First, I use the PRCA to
harvest similar articles for each NIH article. After restricting the set of harvested articles to
those that are published in the 2003-2013 (2011) period and are not themselves NIH articles,
there are a total of 3,171,838 (2,542,714) unique comparison articles. I refer to this set of
comparison articles as the “Full PRCA” sample.
The final set of comparison articles is a subset of the Full PRCA sample. Taking advan-
tage of a similarity score that the PRCA delivers for each harvested article, I am able to
identify the particular comparison article that most closely matches each NIH article and im-
plement a 1-to-1 matching (without replacement) algorithm. I refer to this set of comparison
articles as the “1-to-1 PRCA” sample.
In sum, in order to estimate counterfactual outcomes, I construct four comparison sam-
ples: the “MEDLINE”, “Journal”, “Full PRCA”, and “1-to-1 PRCA” samples. I use four
alternative comparison samples because, a priori, it is not obvious which non-NIH articles
should serve as comparisons. As shown below, the 1-to-1 PRCA sample contains the set of
non-NIH articles that are most similar to the set of NIH articles, making it an intuitively
attractive comparison sample. However, this similarity is driven by the PRCA algorithm,
which, as mentioned, identifies comparison articles using key words and text that are similar
to a corresponding NIH article. This could be problematic if, for example, the PMC man-
date caused “high-quality” non-NIH funded researchers to enter fields similar to those of
NIH-funded researchers. Such a migration would make NIH articles more likely to match to
high-quality articles after the mandate, effectively conditioning away part of the PMC man-
15Ideally, I would use journals published in the same journal issue. However, the journal issue element in
the MEDLINE data is often missing, making this strategy infeasible.
16The key words are called Medical Subject Heading (MeSH) terms, and they are used to classify the
content of each record indexed in MEDLINE. Librarians at the National Library of Medicine (NLM) read
each article and determine which MeSH terms apply to that article. The harvested articles are obtained
from PubMed, a superset of the MEDLINE database.
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date’s effect on citations. Conversely, if the PMC mandate caused “high-quality” non-NIH
funded researchers to move away from fields dominated by NIH-funded researchers, then
NIH articles will be less likely to match to high-quality articles after the mandate, which
would misleadingly inflate the PMC mandate’s effect on citations. Though it seems unlikely
that the PMC mandate caused non-NIH funded researchers to migrate into or out of fields
previously dominated by NIH funded researchers, concerns about implicitly conditioning on
variables affected by the PMC mandate lead me to take a conservative approach and report
results from multiple comparison samples. More generally, it is important not to control
for any variable affected by the PMC mandate (Stuart et al., 2014), which, as discussed be-
low, also leads me to always report estimates with and without conditioning on article-level
covariates.
2.3 Covariates
The data allow me to construct a rich set of article-level covariates. These include the number
of backward citations, the number of backward citations published in open access journals
(which is a proxy for the open access milieu in which an article is published), the number
of unique n-grams (1-, 2-, and 3-grams)17 that an article uses in either the title or abstract,
the number of “top” n-grams an article “originates”, the number “top” n-grams for which
an article is an “early adopter” (these are proxies for article quality that are independent
of citations),18 the number of “Descriptor” Medical Subject Heading (MeSH) terms that
tag an article, the number of “Qualifier” MeSH terms that tag an article (these are proxies
for the disciplinary diversity of an article), the number of authors, an indicator for whether
the author is a corporate entity, a set of indicator variables for the type of institution to
which the first author belongs (e.g. university, hospital, etc.), a set of fixed effects for the
country in which the first author works, a set of indicator variables characterizing an article’s
“Publication Type” (e.g. whether the article is a review article, a clinical trial, etc.), a set
of indicator variables characterizing the languages in which the article is published, and the
number of non-NIH grants that support the article. When the outcome variable is the count
of 2-year forward citations, I also estimate specifications that include journal fixed effects.
Journal fixed effects cannot be included when the outcome variable is the toll access indicator
17In this paper, I define an n-gram as a word (1-gram), a word pair (2-gram), or a word triplet (3-gram).
See Appendix B for more information on the extraction and processing of text from the title and abstract
of MEDLINE articles.
18An article “originates” an n-gram if the article uses the n-gram in the n-gram’s vintage year (first year
the n-gram appears in the MEDLINE corpus). An article is an “early adopter” of an n-gram if the article
uses the n-gram within 5 years of the n-gram’s vintage. A “top” n-gram is one that, compared to all other
n-grams in its vintage, is in the top 0.01% in terms of total mentions in the MEDLINE corpus. See Staudt
et al. (2018) for further details.
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because there is no within-journal variation in this outcome. When the outcome variable is
the toll access indicator, all specifications also include journal start year fixed effects. See
Appendix A for details on all covariates.
2.4 Summary Statistics
Appendix Tables A.1.1 through A.1.4 present summary statistics for each of the four compar-
ison samples (excluding country and journal fixed effects). In the MEDLINE sample during
the pre-mandate period, 13 of the 46 covariates (28.3%) have an absolute standardized mean
difference (between NIH and non-NIH articles) above 0.25, a commonly used rule-of-thumb
to assess the balance of a variable between two groups (Rubin, 2001; Stuart, 2010).19 13
of the 46 covariates are also imbalanced during the post-mandate period. During both the
pre- and post-mandate periods in the Journal sample, 10 (21.7%) covariates are imbalanced.
In the full PRCA sample, 10 (21.7%) and 5 (10.9%) covariates are imbalanced, and in the
1-to-1 PRCA sample, 3 (6.5%) and 2 (4.3%) covariates are imbalanced. Thus, balance tends
to improve as we move from the MEDLINE to the Journal to the Full PRCA Sample, and
the 1-to-1 PRCA sample is very well-balanced. In general, NIH articles tend to cite more
articles, use more top n-grams, are tagged with more MeSH terms, have more authors, are
less likely to have a corporate author, are more likely to be a “Journal Article”, are less
likely to be an “Irregular Article”, and are more likely to be published in English.
It is crucial to stress that identification in a difference-in-difference (DID) setting does
not depend on on the similarity of covariate or outcome variable levels. Indeed, DID allows
for a constant additive (or multiplicative) difference between the mean outcomes of the
the treatment and control groups, only requiring that the trends be similar. Thus, while
covariate balance may increase the plausibility of the identification strategy, the identification
strategy does not depend on balance. The covariates are also potentially useful for increasing
the precision of estimates.
As noted, a potential concern is that the covariates may themselves be impacted by
the PMC mandate (Rosenbaum, 1984). Since the data are a set of pooled cross sections,
covariates cannot be defined as pre-treatment covariates. To partially address this issue,
I restrict the set of covariates to those that are generated prior to the publication of the
article. For instance, the number of backward citations or the number of grants that support
an article are determined prior to publication. In contrast, forward citations, which are not
included in the set of covariates, are determined after publication. Of course, variables that
19The standardized mean difference is defined as (X¯nih − X¯non)/
√
(vnih + vnon)/2, where X¯nih and vnih
are the mean and variance of covariate X for NIH articles and X¯non and vnon are the same quantities for
non-NIH articles.
11
are determined prior to publication may still be impacted by the mandate, so this does not
fully deal with the issue. Indeed, the mandate conceivably impacted all covariates. Thus, I
always present specifications with and without article-level covariates.
3 Research Design
3.1 Details of the NIH Public Access Policy (“PMC Mandate”)
On February 3, 2005 the National Institutes of Health (NIH) issued a policy statement that
requested all NIH-supported articles to be submitted to PubMed Central (PMC), the NIH’s
full-text repository of freely available biomedical research. Regardless of where the article
was published, submission to PMC would make it accessible to anyone with an internet
connection. This request became effective on May 2, 2005.20 Despite the request, a 2006
NIH report to Congress revealed that voluntary compliance with this request was below
4 percent (Suber, 2008). Thus, Congress instructed the NIH to change the request to a
mandate – the “PMC mandate”. On January 11, 2008 the NIH announced that the full text
of all NIH-supported articles accepted for publication on or after April 7, 2008 were to be
submitted, in final peer-reviewed form, to PubMed Central immediately upon acceptance for
publication.21 This mandate for submission to PubMed Central applies to all NIH-funded
articles, regardless of where they are published. Though journals (who retain the copyright
to NIH articles they publish) have the right to delay a published NIH-article’s availability
on PubMed Central for up to one year, it is thereafter freely accessible to anyone.22 By
2012, compliance with the PMC mandate stood at 75 percent, and it continued to increase
thereafter (Grant, 2012; Van Noorden, 2014).
It is worth emphasizing that the PMC mandate neither requires NIH-funded articles
to be published in an open access journal, nor does it require authors to use grant funds
20Specifically, the policy statement read: “beginning May 2, 2005, NIH-funded investigators are requested
to submit to the NIH National Library of Medicine’s (NLM) PubMed Central (PMC) an electronic version of
the author’s final manuscript upon acceptance for publication, resulting from research supported, in whole or
in part, with direct costs from NIH.” http://grants.nih.gov/grants/guide/notice-files/NOT-OD-05-022.html.
21The Public Access Policy was the NIH’s response to Division G, Title II, Section 218 of PL 110-161
(Consolidated Appropriations Act, 2008), which states: “The Director of the National Institutes of Health
shall require that all investigators funded by the NIH submit or have submitted for them to the National
Library of Medicine’s PubMed Central an electronic version of their final, peer-reviewed manuscripts upon
acceptance for publication, to be made publicly available no later than 12 months after the official date of
publication, provided that the NIH shall implement the public access policy in a manner consistent with
copyright law.”
22The embargo period is a “grand compromise” (Salmon, 2016) that seeks to accommodate publisher
concerns about maintaining revenue streams. For overviews about publishing embargoes, see Imboden
(2009), Sutton (2013), and Johnson (2008).
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to purchase open access status for their NIH-funded article in an otherwise subscription-
based journal. The PMC mandate only requires that, no matter where an NIH article is
published (particularly, in this context, regardless of whether it is published in an open or
toll access journal), the post-refereed (but possibly pre-print) version of the article must also
be submitted to PubMed Central, where it will be made fully and freely available to anyone
with an internet connection.
The increase in compliance for NIH articles published after 2008 can be seen in Figure
1. The figure shows the proportion of NIH and non-NIH articles in my sample that have
their full text freely available on PubMed Central (PMC) as of the date I downloaded the
data (10/18/2018). The proportion of NIH articles published between 2003 and 2007 that
are available on PMC as of October 2018 increases from under 20 percent to slightly over
40 percent. There is a steep jump to about 70 percent for articles published in 2008, and
then there is a continual climb to a little over 90 percent for articles published in 2013.
The proportion of non-NIH articles that are available on PMC as of October 2018 increases
steadily from about 6 percent in 2003 to about 23 percent in 2013. Thus, it clear that NIH
articles are much more likely than non-NIH to be available on PMC and there is a sharp
jump in compliance with the PMC mandate for NIH articles published after 2008.23
3.2 Econometric Strategy
The treatment of interest is the requirement to submit an article to PubMed Central immedi-
ately upon acceptance for publication. My core estimates of the effect of this treatment come
from standard difference-in-differences (DID) models. Each article in the sample is either an
NIH article (Ni = 1) or a comparison article (Ni = 0) and is either published before (Pi = 0)
or after (Pi = 1) the PMC mandate. In the difference-in-differences (DID) framework, the
impact of the mandate can be identified by estimating the following equation:
E[Yi|Xi, Ni, Pi] = G[βt + γNi + δ(Pi ×Ni) + ρXi]. (1)
Yi is an outcome variable, βt is a full set of publication year fixed effects, Pi is an indicator
that turns on in 2009, Ni indicates whether an article is NIH-supported, and Xi is a vector of
article-level covariates (see section 2.3). δ is the parameter of interest, measuring the impact
23This figure is similar to figures produced in Bryan and Ozcan (2016). It is constructed using data from
the file PMC-ids.csv.gz, which can be obtained from: https://www.ncbi.nlm.nih.gov/pmc/pmctopmid/. The
file contains information on which articles in PubMed are freely available on PubMed Central. Unfortunately,
the file does not contain information on the date each article went “live” – only that the article is “live”
on the date the data were downloaded (which, in my case, was 10/19/2018). This explains why compliance
seems to be higher in the graph than reports at the time suggest (e.g. 4 percent in 2006 and 75 percent in
2012).
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of the mandate under this model.
When the outcome variable is an indicator designed to measure publication patterns
in biomedicine (e.g. an indicator for being published in a toll access journal), I estimate
equation (1) using all articles in each of my four samples. When the outcome is a citation
measure, I want to estimate equation (1) using only the subset of articles published in
journals actually affected by the PMC mandate. Articles (NIH or comparison) published
in open access journals should not be impacted by the mandate because any researcher can
access and cite these articles, by definition, both before and after the mandate. Thus, for
citation measures, my main DID estimates are obtained using only the sample of articles
published in toll access journals.
For identification using the DID framework, no other variable, unrelated to the PMC
mandate, can differentially affect the outcomes for NIH and comparison articles around 2008.
In the case of citation outcomes, we can directly examine this possibility by estimating
equation (1) using the set of articles published in open access journals to obtain placebo
estimates. In the absence of other variables differentially impacting the citations to NIH
articles, we should not observe a citation effect for articles published in open access journals
because researchers have access to these articles both before and after 2008. Thus, I also
estimate triple differences (DDD) models, with a journal’s open access status as the third
layer of difference, to identify the effect of the PMC mandate on citations. In the DDD
setting, an article is either published in a toll access (“subscription”) (Si = 1) or open access
(Si = 0) journal, and the impact of the mandate can be identified by estimating the following
equation:
E[Yi|Xi, Ni, Pi, Si] = G[βt+γ1Ni+γ2Si+γ3(Si×Ni)+γ4(Pi×Ni)+γ5(Pi×Si)+δ(Pi×Si×Ni)+ρXi].
(2)
In this equation, Si indicates whether article i is published in a toll access journal, and
the other variables are defined as in equation (1). Again, δ is the parameter of interest,
measuring the impact of the PMC mandate under the DDD model.
The main set of estimates are obtained by modeling the conditional mean function, G, as
exponential (which gives rise to the Poisson regression model) and using pseudo maximum
likelihood (PPML) to estimate equations (1) and (2). The reason for this modeling decision
is that the common trends assumption for citations is likely to hold in multiplicative rather
than additive form. In multiplicative form, the assumption implies that, in the absence of
the PMC mandate, citations would increase over time by the same percentage for NIH and
comparison articles, rather than by the same absolute amount. Assuming a proportional
treatment effect leads naturally to an exponential model for the observed citation outcomes
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(Ciani and Fisher, 2013).24 This setup gives the parameter of interest, δ, a semi-elasticity
interpretation – the percent change in the number of citations received by an NIH article
after the PMC mandate. Section 4.2 shows that the results are quite robust to changes in
this modeling decision.
As noted in the introduction, and will be shown in the next section, the citation estimates
are unstable across samples, models, and specifications. Thus, I organize the discussion of
these results around the upper limits of 95% confidence intervals, which will give an indication
of the maximum plausible effects of the PMC mandate on researcher access to the biomedical
literature. Since confidence intervals depend on standard errors as well as point estimates,
it is worth noting how I compute the standard errors. Abadie et al. (2017) suggest that
clustering the standard errors at the journal level may be unnecessarily conservative in this
context since my sample is close to the population of all biomedical articles and there are
few journals (clusters) in the population unobserved in my sample. However, since I am
trying to bound the maximum plausible impacts of the mandate, I opt for the conservative
approach of clustering at the journal level and using these standard errors to compute the
upper limits of 95% confidence intervals. Section 4.2 discusses the results when Eicker-
Huber-White standard errors, which do not allow for arbitrary correlation of error terms
within cluster, are used to compute upper limits of 95% confidence intervals.
4 Results
4.1 Access to the Biomedical Literature
Table 1 displays the Poisson pseudo maximum likelihood (PPML) estimates of the PMC
mandate’s impact on the count of 2-year forward citations received by NIH articles. Panels
A and B display the PPML estimates of δ from the difference-in-differences (DID) model
in equation (1) for articles published in toll access and open access journals, respectively.
Panel C displays the estimates of δ from the triple differences (DDD) model in equation (2).
The table also shows the implied percent changes (%∆) based on the point estimate and the
upper limit of the 95% confidence interval.25,26
24Since citations to an article are often zero, log-linearization is not a feasible strategy in this con-
text. Another possibility is to transform the outcome variable using the inverse hyperbolic sine function:
IHS(Yi) = ln(Yi+
√
1 + Y 2i ). However, the mean for some citation variables is quite small (see tables A.1.1
through A.1.4), making this transformation inappropriate for these outcomes (Bellemare and Wichman,
2018).
25Let δˆ be a point estimate of δ. Then %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1) and
100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
26Appendix Tables A2.1, A2.2, and A2.3 display the PPML coefficient estimates for the covariates not
displayed in Table 1. Tables A2.1 and A2.2 display the estimates using the DID equation (1) for articles
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Overall, the estimates across samples, models, and specifications are quite inconsistent.
The percentage changes implied by the point estimates range from -6.7% to 3.7% for articles
published in toll access journals, -23.4% to to -2.2% for articles published in open access
journals, and from -1.5% to 22.4% for the triple difference. Given the instability of the
estimates, I focus on confidence intervals to determine a plausible upper bound on the PMC
mandate’s impact on the count of 2-year forward citations.
For articles published in toll access journals, the estimates suggest a modest upper bound
on the impact of the mandate – the largest upper limit of a 95% CI, across all samples and
specifications, is obtained using the 1-to-1 PRCA sample and estimating the model without
covariates (column 7). This estimate implies that, at best, the PMC mandate increased the
count of 2-year forward citations by 7.9% for NIH articles published in toll access journals.
However, as noted in Section 3.2, the validity of the DID estimates relies on the assump-
tion that citation ratios between NIH and comparison articles are not changing for reasons
unrelated to the PMC mandate. The estimates using articles published in open access jour-
nals hint that this assumption may be violated. Since these articles are freely available both
before and after the mandate, the relative rate of citation between NIH and comparison
articles published in open access journals should not be affected by the mandate. In fact,
all estimates in Panel B suggest that citations to NIH articles (relative to comparison arti-
cles) published in open access journals declined after the mandate. Moreover, this relative
decline is always estimated to be steeper than the estimated relative decline for NIH articles
published in toll access journals.
The difference in citation decreases for NIH articles (relative to comparison articles) pub-
lished in open access journals (steeper decrease) and toll access journals (shallower decrease)
explains the mostly positive triple difference (DDD) estimates in Panel C. The largest up-
per limit of a 95% CI, over all samples and specifications, is obtained using the MEDLINE
sample and estimating the model without covariates (column 1). It implies that the PMC
published in toll access journals (corresponding to Panel A of Table 1) and articles published in open access
journals (corresponding to Panel B of Table 1). Table A2.3 displays the estimates using the DDD equation
(2) for articles published in any journal type (corresponding to Panel C of Table 1). Across all three tables,
the NIH dummy is always positive and is always precisely estimated (though not always statistically different
from 0), indicating that NIH articles tend to receive more citations than comparison articles. The number of
backward citations (references) and the number backward citations to articles that are, themselves, published
in open access journals are positively related to 2-year forward citations. Also, an article’s use of age 0 and
age 5 top concepts – measures of article quality – and an article’s increased usage of MeSH descriptors – a
measure of disciplinary diversity – are positively associated with the count of 2-year forward citations (see
Staudt et al. (2018), Section 2.3, and the Appendix for details). If the article is a review, comparative study,
meta-analysis, evaluation study, guideline, multi-center study, randomized controlled trial, or clinical trial,
it tends to be cited more often. In contrast, if an article is a case report, observational study, twin study,
or other type of “irregular” article, it tends to be cited less often. Articles published in English tend to be
cited more often and articles having a corporate author are cited much less often.
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mandate may have increased the count of 2-year forward citations by up 46.8%. Thus, in
contrast to the DID estimates for articles published in toll access journals, the DDD esti-
mates do not rule out substantial increases in the count of 2-year forward citations received
by NIH articles after the PMC mandate (though even this upper bound is smaller than the
effect of open access on citations implied by most of the early literature in this area).
Since the upper bounds implied by the DID and DDD estimates of the PMC mandate’s
impact on the count of 2-year forward citations are quite different, it is natural to ask: is
the smaller DID upper bound or the larger DDD upper bound more credible? The answer
largely depends on whether the relative citation rates between NIH and comparison articles
published in open access journals are actually a good counterfactual for what would have
happened, in the absence of the PMC mandate, to the relative citation rates between NIH
and comparison articles published in toll access journals. Visual evidence presented next
indicates that the series of relative citation rates for articles published in open and toll access
journals were not on parallel paths prior to the mandate, suggesting that the DID estimates
using articles published in toll journals may be more credible than the DDD estimates. Also,
interpretation of the DDD estimates is complicated by the fact that, as shown in Section 4.3,
the the toll access indicator in the triple difference is endogenous – that is, the probability
of an article being published in a toll access journal is affected by the PMC mandate. This
also suggests that the DID estimates using articles published in toll access journals may
be preferable to the DDD estimates. Finally, it is worth noting that all of the largest
percent increases implied by the DDD estimates are from specifications that do not include
covariates. For all samples except the Journal Sample, this is primarily because adding
covariates significantly attenuates the negative impact of the PMC mandate on citations
received by NIH articles published in open access journals. For instance, estimates without
covariates obtained using the 1-to-1 PRCA sample, suggest that NIH articles published in
open access journals received 13% fewer citations after the mandate. Adding covariates
attenuates this reduction to 2.2%. This causes the relative differences in citation rates after
the mandate to be smaller between the groups of articles published in toll and open access
journals, giving rise to more modest DDD estimates. Indeed, in DDD models with covariates,
the maximum upper limit of the 95% CIs implies a percent increase of no more than 7.7% –
which is very close to the upper bound of 7.9% implied by the DID estimates obtained using
articles published in toll access journals.
Figure 2 replicates Panels A and B of Table 1 in event study form. Each dot represents
the PPML estimate of the coefficient on the NIH indicator interacted with a calendar year
– that is the percent difference in citations for NIH articles relative to comparison articles
in that year. The black series of dots are estimates obtained using the MEDLINE sample,
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and the blue, red, and green series of dots represent estimates obtained using the Journal,
Full PRCA, and 1-to-1 PRCA samples. Solid dots represent estimates obtained using articles
published in toll access journals and the hollow dots are the estimates obtained using articles
published in open access journals. Finally, Panels A and B represent series of estimates using
specifications without and with covariates.
Consistent with Panel A of Table 1, there is little visual evidence that the PMC mandate
increased citations to NIH articles (relative to comparison articles) published in toll access
journals. If anything, there appears to be a slight decrease. However, consistent with Panel
B of Table 1, it appears that the relative citation rate declines even more rapidly for articles
published in open access journals. If the series constructed using articles published in open
access journals are reasonable counterfactuals for the corresponding series constructed using
articles published in toll access journals, then they represent the baseline of what we would
expect to see in the absence of the mandate – in this case, the relative citation ratio for NIH
articles published in toll access journals would have declined even more in the absence of
the PMC mandate, meaning the mandate had a positive effect on citations to NIH articles
published in toll access journals.
In specifications without covariates, visual evidence suggests that, during the pre-
mandate period, the open access series best tracks the toll access series in the Journal
sample. This sample also produces the smallest post-mandate percent increase in the count
of 2-year forward citations – 7.1% for the point estimate and 31.0% for the upper limit of
the 95% CI. In contrast, the open access series that worst tracks the toll access series during
the pre-mandate period is in the MEDLINE sample, which also produces the largest post-
mandate percent increases. Overall, the visual evidence suggests that the relative citation
rates for articles published in open access journals may not be valid counterfactuals for what
would have happened to relative citation rates for articles published in toll access journals in
the absence of the mandate. Panel B shows that, in all samples, adding covariates substan-
tially reduces the estimated difference between NIH and comparison articles (note that the
scale of the y-axis is more compact when moving from Panel A to B). Otherwise, the broad
trends are the same – both toll access and open access series decline after the PMC mandate,
but the decline is steeper for the open access series. However, the differences become very
small and insignificant, which leads to the small estimated DDD effects observed in Panel C
of Table 1.
Figure 3 replicates Panel C of Table 1 in event study form. In this case, each dot
represents the PPML estimate of the coefficient on the NIH indicator interacted with the
toll access indicator and a calendar year. As before, the black, blue, red, and green series of
dots are estimates obtained using the MEDLINE, Journal, Full, and 1-to-1 PRCA samples.
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Panels A and B represent series of estimates using specifications without and with covariates.
During the pre-mandate period, the relative citation ratio (articles published in toll access
journals relative to articles published in open access journals) of ratios (NIH relative to
comparison articles) is smallest for articles in the Journal sample, followed by articles in
the two PRCA samples, and the MEDLINE sample. In all cases (except, perhaps, the
Journal sample), the effect, on the count of 2-year forward citations, of being an NIH article
published in a toll access journal increases during the pre-mandate period and then continues
to increase after the PMC mandate. This explains the large positive estimates in Panel C
of Table 1 for specifications that do not include covariates. It also again casts doubt on
the validity of the open access series serving as a counterfactual for the toll access series.
When covariates are included, the effect, on the count of 2-year forward citations, of being
an NIH article published in a toll access journal is relatively flat in both the pre and post
mandate periods, which explains the small coefficients in Panel C of Table 1 when covariates
are included.
Taken together, these results suggest that the impact of open access on the count of
2-year forward citations, as facilitated by the PMC mandate, is smaller than suggested
by most of the early literature in this area, and probably much smaller. However, given
the very conservative approach, the upper bound on the portfolio of estimates – obtained by
estimating the triple difference equation (2), without covariates, using the MEDLINE sample
– is still quite high: nearly 47%. That said, more credible estimates – DDD estimates with
covariates and DID estimates using articles published in toll access journals – suggest a much
more modest upper bound of the PMC mandate, perhaps 8%, which is consistent with recent
literature that takes seriously the endogeneity of open access. Moreover, as noted, most of
the point estimates are small, statistically insignificant, and are often negative. The largest –
obtained by estimating the triple difference, without covariates, using the Full PRCA sample
– suggests a statistically insignificant increase of 22.4%, but more credible estimates suggest
an increase of no more than 3.7%. However, from the standpoint of policymakers, even a
probable modest upper bound combined with a possible large upper bound, may be enough
to justify the implementation of the PMC mandate.
Though the previous results suggest that the PMC mandate’s effect on overall access
to the biomedical literature is difficult to pin down – it is likely modest, but I cannot rule
out large effects – it might be possible to more accurately assess the effect on particular
sub-groups of researchers that had limited access to NIH articles prior to the mandate,
gaining access only after it went into effect. To this end, I examine citations from authors
at commercial enterprises and authors in a poor/developing country.
Tables 2 and 3 replicate the results in Table 1 when the outcome variables are the counts
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of 2-year forward citations restricted to those coming from researchers at a commercial
enterprise (Table 2) and researchers in a poor/developing country (Table 3). Again, Panels
A and B display the estimates of the DID model in equation (1) for articles published in toll
access and open access journals, respectively, and Panel C displays the estimates of the DDD
model in equation (2). Similar to the point estimates of the PMC mandate’s impact on total
citations, the point estimates for citations from researchers in poor/developing countries
and at commercial enterprises vary widely across samples, models, and specifications. For
both groups, they tend to be small, are often statistically insignificant, and are sometimes
negative. The more credible point estimates – DDD estimates with covariates and DID
estimates using articles published in toll access journals – suggest that the PMC mandate
increased citations by no more than 4.3% from researchers at commercial enterprises and by
no more than 6.5% from researchers in poor/developing countries.
Returning focus to confidence intervals, when the outcome is citations received from re-
searchers at a commercial enterprise, the largest upper confidence limit for articles published
in toll access journals implies that the mandate increased the count of 2-year forward cita-
tions from these researchers to NIH articles by no more than 9.6%. When the outcome is the
count of 2-year forward citations received from researchers in a poor/developing country, the
largest upper confidence limit suggests a larger plausible effect: 18.0%. However, the esti-
mates for articles published in open access journals are again all negative and most are large
and statistically significant. This again leads to DDD estimates that are larger than DID
estimates for articles published toll access journals (though they are usually not statistically
significant). The upper bounds suggest that the PMC mandate may have increased citations
to NIH articles from researchers at commercial enterprises by up to 62.8% and citations from
researchers in poor/developing countries by up to 49.5%. In specifications with covariates,
these upper bounds are attenuated, but remain large – 30.1% and 29.1%. Thus, like the
total count of 2-year forward citations, I am not able to rule out large increases in 2-year
forward citations coming from researchers at commercial enterprises or in poor/developing
countries. However, even these upper bounds are modest relative to the early literature on
the effects of open access on citations.
It is worth emphasizing that my focus on the maximum percent changes implied by the
upper limits of the 95% confidence intervals, across all samples, models, and specifications,
is a very conservative way to interpret the effects of the PMC mandate on researcher access
to the biomedical literature. I believe this caution is warranted for two reasons. First, to the
extent that policy analyses actually inform policy, the utmost care should be taken not to
overstate results. Second, given the inconsistent and noisy estimates across samples, models,
and specifications, it seems most sensible to focus on bounding the largest plausible effect
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rather than estimate the effect of the PMC mandate. That said, for reasons outlined above, I
view the most credible estimates as coming from the DID estimates using articles published
in toll access journals. Thus, I believe it is unlikely that the PMC mandate increased
the count of 2-year forward citations by more than 7.9%, and unlikely increased the count
of 2-year forward citations from researchers at commercial enterprises and researchers in
poor/developing countries by more than 9.6% and 18.0%. Using the maximum percent
change implied by the DID point estimates as a plausible best guess of the mandate’s effect
on the count of 2-year forward citations suggests an increase of 3.7% for total citations,
4.3% for citations from researchers at commercial enterprises, and 6.5% for citations from
researchers in poor/developing countries.
4.2 Robustness
This section probes the robustness of the main results in Table 1. First, I examine how
the decision to cluster the standard errors at the journal level affects the upper bound on
the plausible effects of the PMC mandate. The standard errors reported in Table 1 are
clustered at the journal level. However, as noted in Section 3.2, this may be unnecessarily
conservative since my sample is close to the population of all biomedical articles and there
are few journals (clusters) in the population unobserved in my sample (Abadie et al., 2017).
Thus, for comparison, Table A3 replicates the results in Table 1 using Eicker-Huber-White
standard errors. For all estimates, the standard errors decline substantially. This, of course,
implies smaller upper limits of the 95% CIs. The largest plausible increase now arises from
the DDD estimates without covariates using the Full PRCA sample, but is cut from 46.8%
to 27.6%. Thus, even with less conservative standard errors, I cannot rule out a fairly
substantial increase in citations after the PMC mandate (though the more credible estimates
in Panel A now suggest an even smaller upper bound – perhaps 5.3%).
Second, I examine the robustness of the results to changing how I measure researcher
access to the biomedical literature. Tables A4.1, A4.2, and A4.3 replicate Tables 1, 2, and 3
using, as the outcome variables, the count of all forward citations ever received (total, from
researchers at commercial enterprises, and from researchers in poor/developing countries)
instead of the count of 2-year forward citations. The estimates are quite similar for both
long-term and short-term citations. For articles published in toll access journals, the DID
estimates suggest a relatively modest upper bound of the mandate’s impact on the total
count of all forward citations ever received: no more than 9.4%, which is slightly larger than
the upper bound of 7.9% for the count of 2-year forward citations. The estimates for the
counts of all forward citations from researchers at commercial enterprises and researchers
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in poor/developing countries also suggest relatively modest upper bounds of the mandate’s
impact – 8.8% and 8.3% – which are actually smaller than the upper bounds of 9.6% and
18.0% for the counts of 2-year forward citations. However, as before, relatively large negative
estimates for articles published in open access journals lead to DDD estimates that tend to
be positive. The DDD estimates suggest an upper bound of 49.4% on the mandate’s impact
on the total count of all forward citations ever received, which is quite similar to the upper
bound of 46.8% for 2-year forward citations. For researchers at commercial enterprises and
researchers in poor/developing countries, the DDD estimates suggest upper bounds of 54.9%
and 52.4% on the count of all forward citations, which compare to the upper bounds of 62.8%
and 51.7% for the counts of 2-year forward citations. Adding covariates again significantly
attenuates these upper bounds to no more than 7.8% (total count of all forward citations),
33.1% (count of all forward citations from researchers at commercial enterprises), and 19.4%
(count of all forward citations from researchers in poor/developing countries). These compare
to 7.7%, 30.1%, and 29.1% for the count of 2-year forward citations. In sum, the results are
robust to changing the outcome from the count of 2-year forward citations to the count of all
forward citations – the upper bound of the mandate’s effects are likely modest, but possibly
large.
Table A5 replicates Table 1 using, as the outcome variable, an indicator for whether an
article receives a forward citation within 2 years of publication. Nearly all DID estimates
for articles published in both toll access and open access journals are negative and statisti-
cally significant. However, the estimates are again almost always more negative for articles
published in open access journals leading to mostly positive, and sometimes statistically
significant, DDD estimates. As with the count, the upper bounds of the effect of the PMC
mandate on the probability of receiving a 2-year forward citation, are larger in specifica-
tions without covariates (15.0%) than specifications with covariates (8.4%). Thus, the upper
bound on the increase in the probability of receiving at least one 2-year forward citation is
smaller (in percentage terms) than the upper bound on the count of 2-year forward cita-
tions. However, since approximately 90% of NIH articles in the pre-mandate period received
at least one citation within 2-years of publication, there was not much room for the mandate
to increase the probability of citation.
Table A6 replicates Table 1 using, as the outcome variable, an indicator for whether an
article ever receives a citation. In contrast to the three previously discussed measures of
access to the biomedical literature, all DID estimates for articles published in toll access
journals and most DID estimates for articles published in open access journals are positive.
That is, after the mandate, NIH articles are more likely than comparison articles to receive at
least one citation. Moreover, unlike the previous outcomes, the magnitude of these changes
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are comparable for articles published in both journal types, leading to small DDD point
estimates. The largest DDD upper limit of the 95% CIs, over all samples and specifications,
implies that the PMC mandate increased the probability of ever receiving a forward citation
by no more than 7.7%, which is a smaller (in percentage terms) upper bound than those
obtained for the other three outcomes. Again, since 94-95% of NIH articles during the
pre-mandate period receive at least one citation, the mandate did not have much room to
increase this probability. In sum, the main takeaways from Table 1 – that the PMC mandate
likely had a modest impact on researcher access to the biomedical literature, but may have
had a large impact – is reinforced by using alternative definitions of access.
Third, I examine the robustness of the results to changes in the assumptions on the
functional form of the conditional mean of the outcome variable. Recall from Section 3.2,
that the results in Table 1 are obtained by modeling the conditional mean of the count of
2-year forward citations using the exponential function and using Poisson pseudo maximum
likelihood (PPML) to estimate the model. The main reason for this choice was my belief
that, for this particular outcome, the common trends assumption underlying DID and DDD
is more plausible in multiplicative rather than additive form (Ciani and Fisher, 2013; Bryan
and Ozcan, 2016). Table A7 replicates Table 1 assuming the parallel trends assumption holds
in additive form. That is, I treat equations (1) and (2) as linear in levels and estimate them
using ordinary least squares (OLS). Though these models are probably misspecified, the OLS
estimates are nevertheless quite consistent with the PPML estimates. Typically the signs
are the same across samples and specifications, and the percent changes implied by the OLS
point estimates and upper 95% confidence limits are often similar to those implied by the
PPML estimates.27 For articles published in toll access journals, the DID estimates suggest
a modest upper bound on the effect of the PMC mandate on the count of 2-year forward
citations: an increase of 6.1% (which is slightly smaller than the PPML estimate). Once
again, substantially more negative estimated impacts for articles published in open access
journals lead to positive DDD estimates, which imply an upper bound of 27.3%, which is
smaller than the bound implied by the PPML estimates, but is still substantial. As before,
all specifications that include covariates imply modest upper bounds. Thus, functional form
assumptions are not driving the main results.
Fourth, I examine whether open access mandates from organizations other than the NIH
are driving the results. As noted in the introduction, the National Institutes of Health
is not the only funder of biomedical science that has introduced open access mandates
27Let δˆ be the estimate of δ in equations (1) or (2). For the linear model in levels, %∆ and %∆ (Upper
95% CI) are computed relative to the mean of the outcome variable, y¯: 100 ∗ (δˆ/y¯) and 100 ∗ (ul/y¯) where
ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
23
in recent years. Indeed, the Registry of Open Access Repositories Mandatory Archiving
Policies (ROARMAP) has documented a precipitous increase in the number of organizations
requiring various forms of open access for the research they support. This gives rise to the
concern that some comparison articles are invalid because they are themselves subject to an
open access mandate of a different organization. To ensure that articles subject to non-NIH
open access mandates are not attenuating the estimated impact of the PMC mandate on
citations, I eliminate these articles from the comparison groups and re-estimate the results
in Table 1, which are presented in Table A8. The DID estimates for articles published in
toll access journals are very similar to the core estimates, and the DID estimates for articles
published in open access journals are identical by construction (because comparison articles
published in open access journals are not eliminated from the sample) except for the 1-to-1
PRCA sample (because, to keep it 1-to-1, I eliminate NIH articles paired with a comparison
article subject to a non-NIH open access mandate). Thus, the DDD estimates are also
very similar, with the upper bound on the PMC mandate’s impact on the count of 2-year
forward citations increasing slightly to 52.2%, with much more modest implied bounds for
specifications with covariates.
Finally, I examine whether the PMC mandate differentially impacted articles supported
through the NIH’s intramural research program relative to those supported extramurally
through NIH grants. The worry is that compliance with the mandate may be different for
these two groups. Figure A1 shows that, though intramurally supported articles are always
submitted to PubMed Central at a higher rate than extramurally supported articles, the
rate of increase in submissions is roughly the same over time. I also examine the differ-
ential impacts by restricting the sample to NIH articles, and estimating equations (1) and
(2), replacing the indicator for an article being NIH with an indicator for an article being
intramurally supported by the NIH. The estimates of δ, which are displayed in Table A9,
allow me to examine whether citations changed differentially for intramurally and extramu-
rally supported NIH articles. Given results in Figure A1, it is unsurprising that almost all
models and specifications suggest no statistically significant differences in the count of 2-year
forward citations between intramurally and extramurally supported NIH articles after the
mandate.
4.3 Publishing Patterns in Biomedicine
Figures 4 and 5 display, for each of the four samples, estimates of how the propensity of NIH
articles to be published in a toll access journal changes over time. Recall from Section 2.1
that toll access is defined in two ways: 1) whether or not a journal is indexed in the Directory
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of Open Access Journals (DOAJ definition) and 2) the fraction of a journal’s articles that
do not belong to the PubMed Central Open Access Subset (PMC-OAS definition). Figure
4 uses the DOAJ definition and Figure 5 uses the PMC-OAS definition. Panels A of each
figure display the results assuming a Poisson model and using pseudo maximum likelihood
(PPML) to obtain the estimates. Panels B of each figure display the results assuming a
linear model in levels and using ordinary least squares (OLS) to obtain the estimates. The
graphs on the left and right are obtained using specifications without and with covariates,
respectively. Each dot represents a point estimate of the NIH indicator interacted with a
calendar year.
Figure 4 shows that, relative to comparison articles in the 1-to-1 PRCA sample, the
propensity of NIH articles to be published in toll access journals was relatively constant
between 2003 and 2006 and then rapidly increased between 2007 and 2010 before settling at
a permanently higher level. Relative to comparison articles in the MEDLINE, Journal, and
Full PRCA samples, the propensity of NIH articles to be published in toll access journals
declined between 2003 and 2007, abruptly changed direction and then rapidly increased
before (usually) settling at a permanently higher level around 2010. These general patterns
are present using both the Poisson and linear models and whether or not covariates are
included in the regression specifications.
Figure 5 shows broadly similar patterns. Relative to comparison articles in the 1-to-1
PRCA sample, the propensity of NIH articles to be published in toll access journals was flat
between 2003 and 2007, and then increased thereafter – though it does not seem to settle
at a permanently higher level. As before, relative to comparison articles in the MEDLINE,
Journal, and Full PRCA samples, the propensity of NIH articles to be published in toll access
journals declined during the pre-mandate period. Relative to comparison articles in the Full
PRCA sample, this propensity sharply reversed course and jumped to a permanently higher
level between 2009 and 2010. In contrast, relative to comparison articles in the MEDLINE
and Journal samples, this propensity did not sharply reverse course, but it did stop declining.
Again, these general patterns are true using both the Poisson and linear models and whether
covariates are included or not.
Taken together, Figures 4 and 5 provide striking visual evidence that, relative to com-
parison articles, the propensity of NIH articles to be published in toll access journals either
increases after the PMC mandate or at least stops decreasing. This is not consistent with the
hypothesis that the PMC mandate induced discrimination, by toll access journals, against
NIH articles. At the very least, any such discrimination seems to have been offset by other
factors – possibly the decisions of editors and the submission behavior of authors.
Table 4 displays estimates of the PMC mandate’s overall impact on the propensity of
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NIH articles to be published in a toll access journal. Panel A uses the DOAJ definition of
toll access and Panel B uses the PMC-OAS definition. For each definition of toll access, two
models are estimated on each of the four samples. First, the conditional mean in equation
(1) is modeled as Poisson and is estimated using PPML. Second, the conditional mean is
modeled as linear in levels and is estimated using OLS.
Using the DOAJ definition of toll access, all estimates, across all models, samples, and
specifications are positive. Estimates from specifications with covariates tend to be a bit
higher than those from specifications without covariates, especially in the MEDLINE and
Journal samples. Estimates using the Poisson model imply percent changes in the propensity
of NIH articles to be published in toll access journals ranging from 0.2% to 1.9% and estimates
using the linear model in levels imply percent changes ranging from 0.1% to 1.6%. In addition
to being positive, all estimates using the Journal, Full PRCA, and 1-to-1 PRCA sample are
statistically significant.
Using the PMC Open Access Subset definition of toll access yields quite similar results in
that most estimates imply a small increase in the propensity of NIH articles to be published
in toll access journals after the PMC mandate. In contrast to the estimates in Panel A,
the the percent changes implied by point estimates using the Poisson and linear models are
between -0.9% and 0% for the MEDLINE and Journal samples (though none are statistically
significant). However, as can be seen in Figure 5, these negative estimates are the result of
the declining propensity of NIH articles to be published in a toll access journal (relative to the
comparison articles) during the pre-mandate period. This trend stops, but fails to reverse,
after the mandate, giving rise to the negative point estimates. The estimates using the two
PRCA samples are always positive and are usually statistically significant. Estimates using
the Poisson model imply percent changes in the propensity of NIH articles to be published
in toll access journals ranging from -0.9% to 1.5% and estimates using the linear model in
levels imply percent changes ranging from -0.7% to 1.3%.
Taken as a whole, this set of estimates suggests that, after the PMC mandate, the
probability that an NIH article is published in a toll access journal increases by a small
amount – perhaps up to 2%. None of the negative point estimates are statistically significant,
and as noted, they arise not because the relative propensity of NIH articles being published
in a toll access journal declines after the mandate, but because this relative propensity was
declining prior to the mandate. Consistent with the visual evidence presented in Figures
4 and 5, these estimates suggest that either the PMC mandate did not induce toll access
journals to discriminate against NIH articles or that any such discrimination was offset by
other factors.
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5 Conclusion
This paper examined the impacts of the National Institutes of Health’s 2008 PubMed Central
(PMC) mandate on researcher access to the biomedical literature and publishing patterns in
biomedicine. Two main findings emerge from the analysis.
First, I find that the effects of the PMC mandate on researcher access to the biomedical
literature are difficult to pin down – point estimates are noisy and vary substantially across
samples, models, and specifications. However, by focusing on the upper limits of confidence
intervals, I am able to bound the plausible increase in citations to NIH articles. This exercise
cannot rule out substantial increases in 2-year forward citations as a result of the mandate.
Indeed, the upper bounds on confidence intervals, over the entire portfolio of estimates,
suggest that the PMC mandate may have increased total citations to NIH articles by up to
46.8%, citations to NIH articles from researchers at commercial enterprises by up to 62.8%,
and citations to NIH articles from researchers in poor/developing countries by up to 49.5%.
All of these upper bounds are obtained using triple difference (DDD) estimates with the toll
access status of a journal as the third layer of difference. As noted, for a variety of reasons
(including the endogeneity of the toll access indicator), I find these estimates less credible
than the estimates obtained using standard difference-in-differences (DID) on the sample of
articles published in toll access journals. These DID estimates suggest much more modest
upper bounds on the effect of the PMC mandate – 7.9% for all 2-year forward citations, 9.6%
for 2-year forward citations from researchers at commercial enterprises, and 18.0% for 2-year
forward citations from researchers in poor/developing countries. These latter estimates are
consistent with most researchers having broad access to the biomedical literature prior to
the mandate (at least in developed countries), providing little scope for the mandate to
increase access. However, it must be stressed that, from the perspective of policymakers,
a likely modest increase in access combined with a possible large increase in access, may
be enough to justify the implementation of the PMC mandate. Moreover, these estimates
do not provide evidence on whether the mandate impacted access for doctors, inventors, or
other consumers of the biomedical literature. Indeed, Bryan and Ozcan (2016) find that the
mandate did increase patent citations to NIH articles after the mandate.
Second, I find no evidence that the PMC mandate induced widespread discrimination,
by toll access journals, against NIH articles that was not offset by other factors such as
author submission behavior. In contrast, the best evidence suggests that the probability
of an NIH article being published in a toll access journal increases after the mandate. If
researchers value “open science”, then, all else equal, they will prefer to publish in journals
that provide widespread access. Prior to the mandate, this preference may have induced
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some researchers to publish some articles in open access journals that would otherwise have
been published in toll access journals. Since the PMC mandate provided universal access
to NIH articles regardless of where they are published, researchers no longer had to take the
openness of the journal into account when deciding where to publish their work. This, along
with journal editors (not publishers) making publication decisions, could account for the up
to 2% increase in the the relative proportion of NIH articles that are published in toll access
journals after the mandate. From the standpoint of policymakers, this result suggests that
a significant potential downside of the PMC mandate – discrimination against NIH articles
– either did not materialize or was offset by mitigating factors.
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Figure 1: Proportion of Articles Available in PubMed Central as of 10/19/2018.
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Notes – The sample includes 956,801 NIH articles and 7,482,563 non-NIH articles published between 2003 and 2013.
Availability in PMC is determined using data from the file PMC-ids.csv.gz, which can be obtained from:
https://www.ncbi.nlm.nih.gov/pmc/pmctopmid/. The file contains information on which articles in PubMed are freely
available on PubMed Central. Unfortunately, the file does not contain information on the date each article went “live” – only
that the article is “live” on the date the data were downloaded (which, in my case, was 10/19/2018).
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Figure 2: DID Dynamic Impacts of the PMC Mandate on Counts of 2-Year Forward
Citations to NIH Articles Published in Open and Toll Access Journals.
Panel A: No Covariates
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Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the PRCA
similarity score. Each dot represents, for a given sample, the PPML point estimate of the NIH indicator interacted with the
calendar year. Solid dots represents estimates using articles published in toll access journals and hollow dots represent articles
published in open access journals. The red vertical line indicates 2008 – the year in which the PMC mandate went into effect.
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Figure 3: DDD Dynamic Impacts of the PMC Mandate on Counts of 2-Year Forward
Citations to NIH Articles.
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(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. Each dot represents, for a given sample, the PPML point estimate of the NIH indicator interacted
with the toll access indicator and the calendar year. The red vertical line indicates 2008 – the year in which the PMC
mandate went into effect.
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Figure 4: Dynamic Impacts of the PMC Mandate on an NIH Article’s Probability of Being
Published in a Toll Access Journal (DOAJ Definition).
Panel A: Poisson Model
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Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2013 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. Each dot represents a point estimate of the NIH indicator interacted with a calendar year. The red
vertical line indicates 2008 – the year in which the PMC mandate went into effect.
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Figure 5: Dynamic Impacts of the PMC Mandate on an NIH Article’s Probability of Being
Published in a Toll Access Journal (PMC-OAS Definition).
Panel A: Poisson Model
-.
03
-.
02
-.
01
0
.0
1
Pa
ra
m
et
er
 e
st
im
at
e
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
MEDLINE Journal
Full PRCA 1-to-1 PRCA
No Covariates
-.
03
-.
02
-.
01
0
.0
1
Pa
ra
m
et
er
 e
st
im
at
e
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
MEDLINE Journal
Full PRCA 1-to-1 PRCA
Covariates
Panel B: Linear Model
-.
03
-.
02
-.
01
0
.0
1
Pa
ra
m
et
er
 e
st
im
at
e
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
MEDLINE Journal
Full PRCA 1-to-1 PRCA
No Covariates
-.
03
-.
02
-.
01
0
.0
1
Pa
ra
m
et
er
 e
st
im
at
e
20
03
20
04
20
05
20
06
20
07
20
08
20
09
20
10
20
11
20
12
20
13
MEDLINE Journal
Full PRCA 1-to-1 PRCA
Covariates
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2013 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
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vertical line indicates 2008 – the year in which the PMC mandate went into effect.
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Table 1. Impacts of the PMC Mandate on 2-Year Forward Citations
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [10.421] [10.421] [10.453] [10.436]
NIH × Post 2008 -0.022 -0.039*** 0.023 -0.032*** -0.069*** -0.059*** 0.036* -0.009
(0.0191) (0.0087) (0.0189) (0.0087) (0.0182) (0.0088) (0.0202) (0.0100)
%∆ -2.1 -3.8 2.3 -3.2 -6.7 -5.7 3.7 -0.9
%∆ (Upper 95% CI) 1.6 -2.2 6.2 -1.5 -3.3 -4.1 7.9 1.0
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [10.226] [10.226] [10.262] [10.262]
NIH × Post 2008 -0.183* -0.075*** -0.044 -0.046** -0.266*** -0.063*** -0.141** -0.022
(0.0982) (0.0245) (0.0999) (0.0230) (0.0826) (0.0200) (0.0562) (0.0218)
%∆ -16.7 -7.2 -4.3 -4.5 -23.4 -6.1 -13.2 -2.2
%∆ (Upper 95% CI) 1.0 -2.6 16.4 -0.1 -9.9 -2.3 -3.1 2.1
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [10.415] [10.415] [10.447] [10.430]
NIH × Post 2008 × TA 0.172 0.016 0.069 -0.008 0.202** -0.015 0.177*** 0.005
(0.1085) (0.0297) (0.1027) (0.0279) (0.0882) (0.0247) (0.0604) (0.0232)
%∆ 18.7 1.6 7.1 -0.8 22.4 -1.5 19.4 0.5
%∆ (Upper 95% CI) 46.8 7.7 31.0 4.8 45.5 3.4 34.4 5.2
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table 2. Impacts of the PMC Mandate on 2-Year Forward Citations from Researchers at
Commercial Enterprises
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [ 0.204] [ 0.204] [ 0.205] [ 0.205]
NIH × Post 2008 -0.005 -0.065*** 0.042 -0.060*** -0.037 -0.080*** 0.038 -0.038**
(0.0254) (0.0165) (0.0255) (0.0166) (0.0256) (0.0179) (0.0254) (0.0188)
%∆ -0.5 -6.3 4.3 -5.9 -3.6 -7.7 3.8 -3.7
%∆ (Upper 95% CI) 4.6 -3.2 9.6 -2.8 1.4 -4.4 9.1 -0.1
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [ 0.214] [ 0.214] [ 0.217] [ 0.218]
NIH × Post 2008 -0.278*** -0.163** -0.096 -0.132* -0.300*** -0.132** -0.175** -0.105
(0.1027) (0.0717) (0.1130) (0.0711) (0.0948) (0.0640) (0.0840) (0.0812)
%∆ -24.3 -15.0 -9.2 -12.4 -25.9 -12.4 -16.1 -10.0
%∆ (Upper 95% CI) -7.4 -2.2 13.3 0.7 -10.8 -0.7 -1.0 5.6
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [ 0.204] [ 0.204] [ 0.205] [ 0.205]
NIH × Post 2008 × TA 0.267** 0.069 0.131 0.046 0.261*** 0.043 0.212** 0.090
(0.1125) (0.0714) (0.1150) (0.0706) (0.0998) (0.0650) (0.0872) (0.0884)
%∆ 30.6 7.1 14.0 4.7 29.9 4.4 23.6 9.4
%∆ (Upper 95% CI) 62.8 23.2 42.8 20.3 57.9 18.6 46.7 30.1
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table 3. Impacts of the PMC Mandate on 2-Year Forward Citations from Researchers in
Poor/Developing Countries
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [ 0.205] [ 0.205] [ 0.207] [ 0.208]
NIH × Post 2008 -0.152*** -0.013 -0.092*** 0.010 -0.155*** -0.016 -0.018 0.063
(0.0337) (0.0291) (0.0340) (0.0296) (0.0325) (0.0291) (0.0512) (0.0523)
%∆ -14.1 -1.3 -8.8 1.0 -14.4 -1.5 -1.7 6.5
%∆ (Upper 95% CI) -8.2 4.5 -2.5 7.0 -8.7 4.2 8.6 18.0
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [ 0.260] [ 0.260] [ 0.263] [ 0.264]
NIH × Post 2008 -0.375*** -0.171*** -0.179** -0.093 -0.397*** -0.115** -0.216*** -0.016
(0.0708) (0.0634) (0.0743) (0.0646) (0.0774) (0.0486) (0.0805) (0.0592)
%∆ -31.3 -15.7 -16.4 -8.9 -32.8 -10.9 -19.4 -1.6
%∆ (Upper 95% CI) -21.0 -4.5 -3.3 3.4 -21.7 -2.0 -5.7 10.5
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [ 0.207] [ 0.207] [ 0.209] [ 0.210]
NIH × Post 2008 × TA 0.240*** 0.102 0.087 0.031 0.246*** 0.029 0.198** 0.017
(0.0825) (0.0782) (0.0857) (0.0795) (0.0871) (0.0610) (0.0947) (0.0836)
%∆ 27.1 10.8 9.1 3.1 27.9 2.9 22.0 1.7
%∆ (Upper 95% CI) 49.5 29.1 29.1 20.5 51.7 16.0 46.8 19.8
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table 4. Impacts of the PMC Mandate on Propensity of NIH Articles to Be Published in a
Toll access Journal
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA DOAJ [ 0.967] [ 0.967] [ 0.967] [ 0.968]
Poisson Model
NIH × Post 2008 0.002 0.011* 0.008 0.015*** 0.012*** 0.015*** 0.018*** 0.019***
(0.0052) (0.0058) (0.0047) (0.0052) (0.0025) (0.0034) (0.0015) (0.0014)
%∆ 0.2 1.1 0.8 1.5 1.2 1.6 1.8 1.9
Linear Model
NIH × Post 2008 0.001 0.007 0.007* 0.011** 0.011*** 0.013*** 0.016*** 0.016***
(0.0045) (0.0048) (0.0042) (0.0045) (0.0021) (0.0029) (0.0014) (0.0013)
%∆ 0.1 0.8 0.7 1.2 1.1 1.3 1.6 1.6
Panel B: TA PMC [ 0.962] [ 0.962] [ 0.963] [ 0.963]
Poisson Model
NIH × Post 2008 -0.009 -0.002 -0.007 0.000 0.003 0.007* 0.013*** 0.015***
(0.0078) (0.0075) (0.0052) (0.0053) (0.0029) (0.0039) (0.0015) (0.0014)
%∆ -0.9 -0.2 -0.7 0.0 0.3 0.7 1.3 1.5
Linear Model
NIH × Post 2008 -0.007 -0.002 -0.005 0.000 0.004* 0.006* 0.012*** 0.013***
(0.0069) (0.0062) (0.0046) (0.0046) (0.0025) (0.0033) (0.0014) (0.0012)
%∆ -0.7 -0.3 -0.5 0.0 0.4 0.6 1.2 1.3
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Observations 8,439,364 8,439,364 6,749,356 6,749,356 4,104,686 4,104,686 1,825,298 1,825,298
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2013 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. All specifications include calendar year and journal start year fixed effects. The article-level covariates
include country fixed effects, backward citations, text-based metrics, MeSH term counts, author counts, and sets of indicators
for whether the author is a corporate entity, institution type, publication type, language, and grant support. The numbers
next to “NIH × Post 2008” are point estimates, δˆ, of δ in equation (1). The numbers in parentheses below are the standard
errors, which are clustered at the aggregated field level (see appendix). For the Poisson model, %∆ is computed as
100 ∗ (eδˆ − 1). For the linear model in levels, %∆ is computed relative to the mean of the outcome variable, y¯: 100 ∗ (δˆ/y¯).
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A Data Sources
I begin with seven sources of raw data: 1) MEDLINE, 2) Web of Science, 3) the Directory
of Open Access Journals (DOAJ), 4) SHERPA/RoMEO, 5) the MeSH vocabulary, 6) Ma-
pAffil, and 7) United Nations National Accounts. From MEDLINE, I obtain a list of unique
article IDs and information about each article’s journal, grant support, publication date,
publication type, author count, MeSH terms, title, and abstract. The unique article IDs are
called PubMed identifiers (PMIDs), which are assigned to articles by the National Library
of Medicine. From Web of Science, I obtain a list of citing PMIDs. I also obtain, for each
citing PMID, a list of cited PMIDs (the citing PMID’s references). From the Directory of
Open Access Journals (DOAJ), I obtain a list of journals identified as being “open access”.
From SHERPA/RoMEO, I obtain journals’ policies on copyright and self-archiving permis-
sions. From the MeSH vocabulary data set, I obtain the tree structure of MeSH terms that
the NLM uses to classify articles in MEDLINE. From MapAffil, I obtain, for each PMID,
information on the affiliation of the first author, including country and type of affiliation
(e.g., university, hospital, etc.). From the United Nations National Accounts, I obtain data
on per capita GDP for a panel of countries. The following subsections will explain each data
set in more detail.
A.1 MEDLINE
MEDLINE is a bibliographic database created and maintained by the U.S. National Library
of Medicine (NLM). The database can be downloaded by anyone, free of charge.28 This
paper uses the 2016 baseline files.29 These are distributed by the NLM as 812 compressed
Extensible Markup Language (XML) files.30
I wrote a series of Perl scripts to extract data from the XML files and place them into
tab-delimited text files.31 The elements that I extract are:32
1. “Status” attribute
2. PMID (and the “Version” attribute)
3. NlmUniqueID
4. MeshHeadingList
5. GrantList
6. PublicationTypeList
28http://www.nlm.nih.gov/bsd/licensee/medpmmenu.html
29https://www.nlm.nih.gov/bsd/licensee/2016 stats/baseline med filecount.html
30XML is a markup language that organizes data into a format that is both human-readable and machine-
readable.
31These scripts (and the rest of the code used to produce the results in this paper) are freely-available in
the following GitHub respository: https://github.com/EconJoe/NIHMandate. The parsers rely heavily on
the XML::Simple module from the Comprehensive Perl Archive Network (CPAN).
32 See https://www.nlm.nih.gov/bsd/mms/medlineelements.html for a description of all elements in
MEDLINE.
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7. PubDate
8. MedlineDate
9. ArticleDate
10. ArticleTitle
11. Abstract and AbstractText
12. Language
The top-level element for each record (article) in the MEDLINE XML files is MedlineCita-
tion. This element has four attributes, but I am only interested in the “Status” attribute.
This attribute indicates how thoroughly the record’s information has been vetted. I only
use records with the status “MEDLINE” as these have undergone the most rigorous quality
review and are the only true MEDLINE records.
The PMID, or PubMed ID, is a unique identifier for every record in MEDLINE. The
PMID element also contains an attribute called “Version”. This attribute is included to deal
with the “versioning” publishing model, in which multiple versions of the same article are
published.33 The PMID element is crucial for linking the MEDLINE and Web of Science
data sets. There are 24,358,442 records in the 2016 baseline files. Because 317 PMIDs have
several “versions”, there are only 24,358,073 unique PMIDs.
The NLMUniqueID element is a seven, eight, or nine character identifier that uniquely
identifies the journal in which a record is published. It is crucial for linking jounal-level infor-
mation within MEDLINE and other NLM sources. There are 23,395 unique NLMUniqueID
in the 2016 baseline files. The mean NLMUniqueID contains 1,041 articles and the median
contains 89. 2,579 NLMUniqueID contain only a single article and The Journal of Biological
Chemistry contains 170,684 articles. In addition to using the NLMUniqueID as a linking
variable, I also use it to estimate journal fixed effects and to cluster the standard errors at
the journal level in some of the models in the paper.
Unfortunately, other sources of journal-level data, such as DOAJ, do not use the NL-
MUniqueID. Instead, they use the International Standard Serial Number (ISSN) to identify
journals. Thus, to link journal-level information in MEDLINE to these other data sources, I
need to use the ISSN. The ISSN is an eight-character value that uniquely identifies periodi-
cal publications, including journals. It is assigned by ISSN National Centers, not the NLM.
Thus, it is more universal and more useful than the NLMUniqueID for linking to non-NLM
sources. If a journal has both a print and electronic format, then each format will receive a
separate ISSN. Fortunately, MEDLINE typically include all formats, which allows me to link
data at the journal-level regardless of which ISSN format is used in non-NLM sources. The
ISSNLinking element is an ISSN that links all formats of the same journal. This element
also helps to uniquely identify journals with multiple ISSNs.
The MeshHeadingList element contains a list of all MeSH (Medical Subject Heading)
terms assigned to the record. MeSH terms are used to classify the content of each record
indexed in MEDLINE. NLM librarians read each article and determine which MeSH terms
33PLoS Contents is the only journal indexed in MEDLINE that uses the versioning model of publishing.
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apply to that article. Thus, they are librarian-supplied, not author-supplied. This eliminates
concerns about authors strategically choosing MeSH terms. The MeshHeadingList contains
the following elements: DescriptorName and QualifierName, each of which have the attribute
“MajorTopicYN”. As suggested by the names, DescriptorName describes the record content,
QualifierName qualifies the description, and “MajorTopicYN” indicates whether the MeSH
term is a major or minor topic of the article. For instance, “Fetal Growth Retardation”
might be a descriptor and “complications” might qualify the descriptor. The MeSH terms
are crucial for linking MEDLINE and the MeSH vocabulary. The article-level covariates
computed using the MeSH terms are: the 1) total number of descriptor terms and 2) total
number of qualifying terms that tag each article.
The GrantList element contains a list of all grants that are acknowledged by a record. It
includes the grant number as well as the funding agency. I use the funding agency to identify
which are records are NIH-funded. The article-level covariates computed using the grant list
are: 1) an indicator for whether an article is NIH funded and 2) the count of non-NIH grants
that support an article.
The PublicationTypeList element contains a list of all publication types that characterize
an article. Like MeSH terms, these publication types are librarian-supplied. Examples of
publication types include “Journal Article”, “Review”, and “Retracted Publication”. There
are XX publication types34, and I combine them into 21 groups to include as article-level
covariates in models that I estimate. Two of the publication types are “Research Support,
N.I.H., Extramural” and “Research Support, N.I.H., Intramural”. I use this as an additional
source of information about which records are NIH funded.
MEDLINE has three date elements that I use to determine the publication date of each
record: PubDate, MedlineDate, and ArticleDate. PubDate follows a standard dating format,
making it very easy to identify the Year element. When dates do not follow this standard
format, they are found in the element MedlineDate. For these non-standard dates, I manually
code the year. In some cases, there is a year range instead of a single year. For these cases, I
take the first year in the range as the publication year. The element ArticleDate contains the
date that a publisher first publishes an electronic version of an article. ArticleDate always
follows a standard dating format, making it easy to identify the Year element. Often, the
date information in the PubDate or MedlineDate elements differs from the date information
in the ArticleDate element. This is because the electronic and print versions of articles
are often published on different dates. I take the minimum year as the relevant year of
publication. Typically, the PubDate and MedlineDate Year elements do not differ by more
than a year from ArticleDate Year element. I use the publication year to estimate a set of
year fixed effects in all models and also to define the pre and post PMC mandate periods
(before and after 2008).
The element ArticleTitle contains the complete English title for each record. If the article
is originally published in a different language, it is translated to English. The elements
Abstract and AbstractText contain the abstract for each record published in an English
language journal. Unlike titles, abstracts are not translated if they are originally published
in another language. The titles and the abstracts for each record are used to construct text
metrics that are included as article-level covariates in estimated models. See Appendix B
34See here for the full list: https://www.nlm.nih.gov/mesh/pubtypes.html
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for additional information on processing title and abstract text.
The element Language contains information on the language in which an article is pub-
lished. I create 10 indicator variables for 10 languages, which serve as article-level covariates
in models that I estimate. These languages are: English, German, French, Russian, Japanese,
Spanish, Italian, Chinese, and Other. I also include an additional indicator for articles whose
language is undetermined.
A.2 Web of Science
Clarivate Anlytics Web of Science (WOS) is a citation indexing database. Indeed, it is the
most widely used source of citation data.35 Unlike the rest of the data used in this paper,
the WOS data is not freely available. Instead, access to the data was negotiated in 20XX
and the data were delivered in December 2014. The data were delivered as 32 XML files
and include all articles published between 1950 and 2014 that are indexed in both WOS and
MEDLINE. There are 13,878,957 citing articles. The mean number of references is 22.76,
the median is 17, maximum of 6,310, and the standard deviation is 25.27. There are a total
of 14,328,197 cited articles. These receive an average of 22.04 citations, a median of 8, a
maximum of 251,686, and a standard deviation of 114.98.
WOS provides a wide variety of information about each article. However, for each article,
I only extract the PMID along with all of the PMIDs cited by the article (i.e, each PMID
and its references). The PMID allows me to link WOS records to MEDLINE records. The
references for each PMID allow me to construct various citation measures for each article and
author. Specifically, it allows me to construct the following outcome variables: total 2-year
forward citations, 2-year forward citations received by articles associated with a commercial
firm (see MapAffil data below), and 2-year forward citations received by articles associated
with poor/developing countries (see UN National Accounts data below). These data also
allow me to construct the following article-level covariates: count of backward citations and
count of backward citations to articles published in open access journals.
A.3 Directory of Open Access Journals (DOAJ)
The Directory of Open Access Journals (DOAJ) is an online directory that indexes peer-
reviewed open access journals. It began as a project at Lund University in 2002, but is now
an independent organization. The database can be downloaded by anyone, free of charge.36
The database is updated daily, and past versions are not readily available. I downloaded
the file on November 11, 2016, and will make it available upon request. The database is
distributed as a CSV (comma-separated) file. I use journals’ International Standard Serial
Number (ISSN) to match DOAJ data to the MEDLINE data.37
35Another common citation indexing database is Elsevier’s Scopus.
36Go to http://doaj.org/faqmetadata, and click ”Download the file to your computer”.
37See http://doaj.org/faqsearchresults for the fields contained in the DOAJ data file. This data allows
me to construct one of the main outcome variables of interest: an indicator variable for whether an article
is published in a toll access journal.
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A.4 PubMed Central Open Access Subset (PMC-OAS)
The PubMed Central Open Access Subset (PMC-OAS) is the set of open access articles in
PubMed Central.38 These articles are linked MEDLINE using their PMID. The fraction of
articles that do not belong to the PMC-OAS (that is, are toll access) is computed for each
journal (NLMID). This fraction, is used as a proxy for the journal’s open access status.
A.5 SHERPA/RoMEO
SHERPA/RoMEO is an online repository of journal-level data on copyright and self-archiving
permissions. Based on these policies, each journal is classified into one of four color-coded
categories: 1) “Green” – can archive pre-print and post-print or publisher’s version/PDF, 2)
“Blue” – can archive post-print (i.e. final draft post-refereeing) or publisher’s version/PDF,
3) “Yellow” – can archive pre-print (i.e. pre-refereeing), 4) “White” – archiving not formally
supported. I used the ISSNs of each MEDLINE journal to query the repository’s API to
obtain the data.39
A.6 MeSH Vocabulary
The MeSH vocabulary is a small set of XML files that contains all MeSH terms and infor-
mation about each term (e.g., the date it was introduced). These files are freely available
from the National Library of Medicine (NLM).40 I extract the following information for each
MeSH term: 1) the term itself, 2) a unique ID assigned to each MeSH term, and 3) the
branches of the MeSH tree on which the term is located. The MeSH terms can map to mul-
tiple branches on the MeSH tree. I use MeSH branches to characterize the field of articles,
which is described in Appendix C.
A.7 MapAffil
MapAffil (Torvik, 2015) is a data set containing information on the affiliation of MEDLINE
articles’ authors. The 2016 tranche of data consist of 37,412,190 PMID-authors. I extract
information on the country and type of institution that characterize each affiliation and use
the PMID to link this information to MEDLINE.
There are 929 countries in the MapAffil data. Country information is used to com-
pute author country fixed effects. Each affiliation is categorized into eight institution types:
commercial, educational, hospital, educational/hospital, government, military, other orga-
nization, or unknown. Institution type information is used to construct a set of indicator
variables characterizing the type of author affiliation for each article.
I also use the country and institution type information to construct citation measures that
only include citations from authors affiliated with particular countries or institution types.
In particular, I am able to identify citations that come from authors in poor/developing
countries and who are affiliated with commercial enterprises.
38https://www.ncbi.nlm.nih.gov/pmc/tools/openftlist/
39http://www.sherpa.ac.uk/romeo/apimanual.php
40http://www.nlm.nih.gov/mesh/filelist.html
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A.8 United Nations National Accounts
The UN National Accounts main aggregates are updated yearly by Economic Statistics
Branch of the UN Statistics Division. I use country aggregates on per capita GDP at current
prices (U.S. dollars).41 The data contain yearly GDP information on 220 countries between
1970 and 2015, though I only use data between 2003 and 2013. When data is missing for a
particular country-year, I linearly interpolate the value. For 2003-2013, the mean per capita
GDP is $14,681 (SD=$23,057) and the median is $4,809.
I use this data to classify each country into per capita GDP quintiles by year. I then link
this country-year level data to MapAfill, which enables me to link GDP quintile information
to each MEDLINE article. I use this information to identify citations that come from
authors in poor/developing countries. In this case, I define a country as poor/developing for
a particular year if it is in one of the bottom two quintiles of the per capita GDP distribution
in that year.
B Processing Title and Abstract Text
This section draws heavily on Staudt et al. (2017), which itself draws heavily on Packalen
and Bhattacharya (2015). As noted in Appendix A, I use a Perl script to extract the
ArticleTitle, Abstract, and AbstractText elements from each record (article) indexed in the
812 MEDLINE 2016 Baseline Files. After extraction, the script indexes all words, word pairs
and word triplets (1-, 2-, and 3-grams). It then processes each n-gram by performing the
following operations:
1. Convert all text to lower-case.
2. Eliminate 2- and 3-grams with words that cross the following characters: ,.?!;:)(}{][–.
3. Eliminate all remaining characters that are not alphanumeric.
4. Eliminate all n-grams that contain words appearing in the stopword list provided by the
NLM at this address: http://mbr.nlm.nih.gov/Download/2009/WordCounts/wrd stop
5. Eliminate all n-grams that contain the following character sequences: web, www, http,
pubmed, medline, clinicaltrialsgov.
6. Eliminate all n-grams that contain more than two adjacent numbers.
7. Eliminate all n-grams that have a length of less than three characters.
8. Keep all 1-grams with character length 3-29, 2-grams with character length 7-59, and
3-grams with character length 11-89.
9. Stem each word from each n-gram using the module Lingua::Stem from the Compre-
hensive Perl Archive Network (CPAN).
41See: http://data.un.org/Data.aspx?q=GDP+per+capita&d=SNAAMA&f=grID%3a101%3bcurrID%3aUSD%3%3a1
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10. Index all the processed n-grams from each title and abstract into 812 tab-delimited
text files corresponding to the 812 MEDLINE XML files.
Once they are processed, I identify each n-gram’s “vintage” (“birth”) year – that is,
the year the n-gram first appears in the MEDLINE corpus. After an n-gram appears in the
MEDLINE corpus, I am able to identify all articles that use the n-gram in a title or abstract.
I use this information to identify, for every vintage, a set of “top” n-grams. An n-gram is
a top n-gram if it is in the top 0.01 percent of all n-grams in its vintage, in terms of the
total number articles that mention it after birth. Top n-grams are identified within vintage
because n-grams from earlier vintages will have more time to accumulate article mentions
than n-grams from later vintages. Thus, it does not make sense to compare n-grams that
have different vintages.
I use this information to construct three article-level covariates. First, I compute the
count of top n-grams that an article originates. An article originates a top n-gram if it uses
the top concept in its vintage year. If multiple articles use a top n-gram in its vintage year,
then that particular n-gram has multiple originators. Second, I compute the count of top
n-grams that an article adopts early – i.e. within 5 years of the n-gram’s vintage. Finally, I
compute the total number of n-grams, regardless of vintage or “top” status, that an article
uses in its title or abstract.
C Aggregating MeSH Terms to Construct Fields
This section draws heavily on the Appendix of Staudt et al. (2017). They devise an algorithm
which uses the Medical Subject Headings (MeSH) that tag most articles in MEDLINE to
characterize the fields to which each article belongs. Note that Staudt et al. (2017) use the
2014 MEDLINE baseline files, but the current paper uses the 2016 MEDLINE baseline files.
There are 27,883 raw terms in the 2016 MeSH vocabulary and they vary widely in their
descriptive detail. For instance, some articles are tagged with general terms such as Body
Regions and some are tagged with more detailed terms such as Peritoneal Stomata. Thus,
in order to construct comparable fields, I aggregate all MeSH terms to a similar level of
descriptive detail.
To understand the aggregation method, it is important to first understand how MeSH
terms are organized. MeSH terms have a hierarchical structure. At the top of the hierarchy
(first-level terms) are 16 very general terms such as Anatomy, Organisms, and Diseases. Each
of these 16 first-level terms are identified by a unique capital letter. For instance, Anatomy
is identified by the letter A, Organisms is identified by B, and so on. Beneath each of these
first-level MeSH terms is a group of second-level MeSH terms. For instance, Body Regions
is a second-level MeSH term beneath the top-level term Anatomy. Each second-level MeSH
term is identified by the capital letter of the first-level MeSH term it is beneath and by
two numbers. For instance, Body Regions is identified by A01. Beneath each second-level
MeSH term is a group of third-level MeSH terms identified by the capital letter of the first-
level term it is beneath, the two numbers of the second-level term it is beneath, and three
subsequent numbers. For instance, Anatomic Landmarks is a third-level MeSH term under
Body Regions and is identified as A01.111. This structure continues to depths of up to 12
levels.
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Aggregating MeSH terms (that is, classifying lower level MeSH terms as a part of higher
level MeSH terms) is complicated by the fact that most MeSH terms fall beneath multiple
higher level MeSH terms. Consider the MeSH term Asthma. This term has four separate
identifiers: C08.127.108, C08.381.495.108, C08.674.095, and C20.543.480.680.095. Thus,
Asthma falls under the first level MeSH term Diseases (identified by C). It also falls under
the second-level terms Respiratory Tract Diseases (C08) and Immune System Diseases (C20).
The problem arises because MEDLINE records only contain the MeSH terms themselves, not
their identifiers. For instance, if a MEDLINE record is tagged with the MeSH term Asthma,
it is not clear whether this is the Asthma that is beneath Respiratory Tract Diseases (C08)
or Immune System Diseases (C20).
Consider aggregating the raw MeSH term Asthma to the second-level – i.e., splitting it
between the second-level terms Respiratory Tract Diseases and Immune System Diseases. I
opt to simply assign half to each higher level term. Thus, an article originally tagged with
the raw term Asthma is now tagged with two second-level terms, each weighted by 1/2.
Now consider aggregating the raw MeSH term Asthma to the fourth-level. In this case,
Asthma must be split between the following fourth-level terms:
• Lung Diseases, Obstructive [C08.381.495] from C08.381.495.108
• Hypersensitivity, Immediate [C20.543.480] from C20.543.480.680.095
• Asthma [C08.127.108] from C08.127.108
• Asthma [C08.674.095] from C08.381.495.108
In this case, a quarter of the raw term Asthma is assigned to each of these four fourth-level
terms. Thus, overall, 1/4 will be assigned to Lung Diseases, Obstructive, 1/4 to Hypersen-
sitivity, Immediate, and 1/4+1/4=1/2 to Asthma itself. Thus, an article originally tagged
with the raw term Asthma is now tagged with three fourth-level terms, two weighted by 1/4
and one weighted by 1/2.
A last complication is that most article are tagged by multiple raw MeSH terms. As an
example, suppose that, in addition to being tagged with Asthma, an article is also tagged with
the raw terms Neck (identified by A01.598) and Health Information Exchange (identified by
L01.700.253, L01.399.500.500, L01.313.500.500, and E05.318.308.940.968.625.500.500). By
the process discussed above, 1/4 of Health Information Exchange will be assigned to each of
the four fourth-level MeSH terms: Health Information Exchange itself (L01.700.253), Health
Information Management (L01.399.500), Medical Informatics (L01.313.500), and Data Col-
lection (E05.318.308). Since the lowest level of aggregation for Neck is the third-level, it
cannot be assigned to a fourth-level term. In this Neck is simply eliminated – it is too highly
aggregated.
Each of the original remaining MeSH terms, Asthma and Health Information Exchange,
are assumed to receive equal weight in characterizing the article. Under this assumption,
the article will be apportioned to each fourth level MeSH term as follows:
• 1/2*1/4=1/8 to Lung Diseases, Obstructive
• 1/2*1/4=1/8 to Hypersensitivity, Immediate
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• 1/2*1/4=1/8 to Asthma
• 1/2*1/4=1/8 to Asthma
• 1/2*1/4=1/8 to Health Information Exchange
• 1/2*1/4=1/8 to Health Information Management
• 1/2*1/4=1/8 to Medical Informatics
• 1/2*1/4=1/8 to Data Collection
Obviously 1/8+1/8+1/8+1/8+1/8+1/8+1/8+1/8=1. Thus, an article that was origi-
nally tagged by the three raw MeSH terms Asthma, Neck and Health Information Exchange
is now apportioned between seven different fourth-level MeSH terms – Asthma receiving a
weight of 1/8+1/8 = 1/4 and the other six receiving a weight of 1/8 each.
In general, each MEDLINE article is apportioned across aggregated MeSH terms in
two stages. First, the original MeSH terms are equally apportioned across the higher-level
MeSH terms of which they are a part (e.g. apportion Asthma equally across Lung Diseases,
Obstructive, Hypersensitivity, Immediate, Asthma, and Asthma. Second, the higher-level
MeSH terms are weighted by the inverse of the number of original MeSH terms of the proper
level that tag the article (e.g. the hypothetical article was tagged by three original MeSH
terms, but only two at the proper level of aggregation, and so each is weighted by 1/2).
Each article is assigned to the most highly weighted fourth-level MeSH term. In the
example above, the article would be assigned to Asthma, which received a weight of 1/4.
Ties are broken randomly. Thus, each article is assigned to a single aggregated “field”. These
fields are used to cluster standard errors.
I also use raw MeSH terms to develop and alternative characterization of an article’s field.
In particular, I first identify the major Descriptor MeSH terms for each article. If there are
multiple major MeSH terms, I choose the first listed as the raw term to characterize the
field.
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Figure A1: Proportion of Intramurally and Extramurally Supported NIH Articles Available
in PubMed Central as of 10/19/2018.
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Notes – The sample includes 921,620 Extramurally supported NIH articles and 35,181 intramurally supported NIH articles
published between 2003 and 2013. Availability in PMC is determined using data from the file PMC-ids.csv.gz, which can be
obtained from: https://www.ncbi.nlm.nih.gov/pmc/pmctopmid/. The file contains information on which articles in PubMed
are freely available on PubMed Central. Unfortunately, the file does not contain information on the date each article went
“live” – only that the article is “live” on the date the data were downloaded (which, in my case, was 10/19/2018).
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Table A1.1: Summary Statistics for the MEDLINE Sample.
NIH Pre Comp. Pre NIH Post Comp. Post All
Mean SD Mean SD Std. Diff. Mean SD Mean SD Std. Diff. Mean SD
Outcome Variables
2-Yr For. Cites 10.41 17.97 3.78 10.55 0.45 7.13 18.85 2.60 8.20 0.31 3.79 10.98
All-Yr For. Cites 35.15 68.67 13.31 38.67 0.39 10.08 27.37 3.66 12.15 0.30 9.84 32.54
2-Yr For. Cites (Indicator) 0.89 0.31 0.61 0.49 0.69 0.74 0.44 0.50 0.50 0.51 0.58 0.49
All-Yr For. Cites (Indicator) 0.94 0.24 0.75 0.43 0.54 0.75 0.43 0.53 0.50 0.48 0.66 0.47
2-Yr Forward Cites (Com. Enterprise) 0.20 0.80 0.10 0.60 0.15 0.10 0.57 0.05 0.39 0.12 0.08 0.53
2-Yr Forward Cites (Dev. Country) 0.21 0.81 0.15 1.48 0.05 0.07 0.66 0.06 0.69 0.02 0.11 1.11
TA Journal (DOAJ) 0.97 0.18 0.96 0.20 0.05 0.90 0.30 0.88 0.32 0.05 0.92 0.27
TA Journal (PMC-OAS) 0.96 0.18 0.98 0.15 -0.08 0.87 0.30 0.88 0.30 -0.03 0.93 0.25
Covariates
Backward Cites 36.15 30.92 17.11 24.30 0.68 37.62 35.18 19.39 26.24 0.59 20.41 27.02
OA Backward Cites 0.52 1.41 0.25 0.98 0.22 1.34 2.70 0.67 1.83 0.29 0.52 1.60
Age 0 Top Concepts 0.02 0.20 0.01 0.16 0.06 0.03 0.22 0.02 0.19 0.05 0.02 0.18
Age ≤ 5 Top Concepts 0.33 0.94 0.19 0.72 0.16 0.27 0.84 0.17 0.67 0.13 0.20 0.72
Total Concepts 138.42 47.04 101.70 60.68 0.68 120.35 67.83 91.69 68.29 0.42 100.17 65.16
Total MeSH Descriptors 13.86 5.24 10.75 5.62 0.57 13.22 5.37 10.27 6.07 0.52 10.84 5.89
Total MeSH Qualifiers 9.01 5.80 6.44 5.06 0.47 8.68 5.93 6.26 5.35 0.43 6.63 5.35
Author Count 5.34 3.89 4.32 6.71 0.19 6.17 6.12 4.89 13.18 0.12 4.75 10.11
Corporate Author 0.00 0.01 0.01 0.11 -0.16 0.00 0.01 0.01 0.09 -0.13 0.01 0.10
Journal Article 0.99 0.12 0.91 0.29 0.36 0.98 0.15 0.91 0.28 0.28 0.92 0.27
Research Support, U.S. Gov’t, Non-P.H.S. 0.14 0.35 0.03 0.16 0.43 0.13 0.34 0.03 0.16 0.39 0.04 0.19
Research Support, ARRA 0.00 0.00 0.00 0.00 . 0.00 0.05 0.00 0.01 0.07 0.00 0.01
Research Support, Non-U.S. Gov’t 0.48 0.50 0.34 0.47 0.29 0.48 0.50 0.39 0.49 0.19 0.38 0.49
Review Article 0.11 0.32 0.12 0.33 -0.02 0.12 0.32 0.10 0.30 0.06 0.11 0.31
English Abstract 0.00 0.02 0.07 0.26 -0.40 0.00 0.02 0.06 0.23 -0.34 0.06 0.23
Case Report 0.01 0.09 0.08 0.28 -0.36 0.01 0.10 0.07 0.26 -0.31 0.07 0.25
Comparative Study 0.12 0.32 0.09 0.29 0.07 0.06 0.24 0.06 0.23 0.01 0.08 0.26
Meta-Analysis 0.00 0.05 0.00 0.06 -0.02 0.01 0.07 0.01 0.08 -0.02 0.00 0.07
Evaluation Studies 0.02 0.14 0.02 0.15 -0.03 0.01 0.11 0.02 0.13 -0.04 0.02 0.14
Guideline 0.00 0.02 0.00 0.05 -0.05 0.00 0.03 0.00 0.04 -0.03 0.00 0.04
Multicenter Study 0.02 0.13 0.01 0.12 0.03 0.02 0.14 0.01 0.12 0.05 0.01 0.12
Observational Study 0.00 0.00 0.00 0.00 -0.00 0.00 0.03 0.00 0.04 -0.01 0.00 0.03
Randomized Controlled Trial 0.03 0.16 0.02 0.15 0.01 0.03 0.17 0.02 0.15 0.04 0.02 0.15
Technical Report 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 -0.00 0.00 0.01
Twin Study 0.00 0.05 0.00 0.02 0.05 0.00 0.04 0.00 0.02 0.05 0.00 0.02
Validation Studies 0.01 0.10 0.01 0.09 0.02 0.01 0.08 0.01 0.08 0.01 0.01 0.09
Clinical Trial 0.03 0.16 0.03 0.16 -0.00 0.02 0.13 0.01 0.12 0.02 0.02 0.14
Irregular Article 0.02 0.14 0.12 0.32 -0.39 0.04 0.19 0.11 0.31 -0.28 0.10 0.31
Other Language 0.00 0.01 0.02 0.14 -0.21 0.00 0.01 0.01 0.12 -0.17 0.02 0.12
English 1.00 0.02 0.89 0.31 0.48 1.00 0.02 0.92 0.26 0.40 0.92 0.27
German 0.00 0.00 0.01 0.11 -0.16 0.00 0.00 0.01 0.10 -0.14 0.01 0.10
French 0.00 0.01 0.02 0.12 -0.18 0.00 0.01 0.01 0.10 -0.14 0.01 0.11
Russian 0.00 0.01 0.01 0.10 -0.15 0.00 0.01 0.01 0.09 -0.13 0.01 0.09
Japanese 0.00 0.00 0.01 0.11 -0.15 0.00 0.00 0.01 0.09 -0.12 0.01 0.09
Spanish 0.00 0.01 0.01 0.11 -0.15 0.00 0.01 0.01 0.10 -0.14 0.01 0.10
Italian 0.00 0.00 0.00 0.06 -0.08 0.00 0.00 0.00 0.04 -0.06 0.00 0.05
Chinese 0.00 0.01 0.02 0.15 -0.21 0.00 0.01 0.02 0.14 -0.20 0.02 0.13
Other Grant Count 0.07 0.37 0.02 0.21 0.17 0.17 0.88 0.05 0.39 0.17 0.05 0.38
Commercial Affiliation 0.01 0.10 0.02 0.15 -0.11 0.01 0.09 0.02 0.14 -0.09 0.02 0.14
Educational Affiliation 0.65 0.48 0.45 0.50 0.41 0.65 0.48 0.49 0.50 0.33 0.49 0.50
Eductional/Hospital Affiliation 0.16 0.37 0.16 0.37 -0.00 0.15 0.36 0.17 0.37 -0.05 0.16 0.37
Government Affiliation 0.00 0.05 0.01 0.07 -0.05 0.00 0.05 0.01 0.07 -0.05 0.00 0.07
Hospital Affiliation 0.07 0.25 0.11 0.32 -0.16 0.07 0.26 0.10 0.30 -0.10 0.10 0.30
Military Affiliation 0.00 0.03 0.00 0.04 -0.03 0.00 0.03 0.00 0.04 -0.03 0.00 0.04
Organization Affiliation 0.09 0.29 0.10 0.30 -0.02 0.10 0.29 0.09 0.29 0.00 0.10 0.29
Unkown Affiliation 0.02 0.13 0.15 0.35 -0.49 0.02 0.15 0.12 0.33 -0.39 0.12 0.33
Observations 448,326 3,605,437 508,475 3,877,126 8,439,364
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Table A1.2: Summary Statistics for the Journal Sample.
NIH Pre Comp. Pre NIH Post Comp. Post All
Mean SD Mean SD Std. Diff. Mean SD Mean SD Std. Diff. Mean SD
Outcome Variables
2-Yr For. Cites 10.41 17.97 4.77 11.89 0.37 7.13 18.85 3.13 9.08 0.27 4.58 12.10
All-Yr For. Cites 35.15 68.67 16.69 43.62 0.32 10.08 27.37 4.40 13.47 0.26 11.81 35.90
2-Yr For. Cites (Indicator) 0.89 0.31 0.72 0.45 0.44 0.74 0.44 0.57 0.49 0.36 0.67 0.47
All-Yr For. Cites (Indicator) 0.94 0.24 0.84 0.36 0.31 0.75 0.43 0.60 0.49 0.33 0.73 0.44
2-Yr Forward Cites (Com. Enterprise) 0.20 0.80 0.12 0.68 0.11 0.10 0.57 0.06 0.43 0.09 0.10 0.58
2-Yr Forward Cites (Dev. Country) 0.21 0.81 0.18 1.70 0.02 0.07 0.66 0.07 0.77 0.00 0.13 1.23
TA Journal (DOAJ) 0.97 0.18 0.97 0.18 -0.00 0.90 0.30 0.89 0.31 0.02 0.93 0.26
TA Journal (PMC-OAS) 0.96 0.18 0.98 0.15 -0.08 0.87 0.30 0.89 0.29 -0.05 0.93 0.24
Covariates
Backward Cites 36.15 30.92 20.83 25.66 0.54 37.62 35.18 22.66 27.47 0.47 23.95 28.18
OA Backward Cites 0.52 1.41 0.31 1.09 0.17 1.34 2.70 0.78 1.97 0.24 0.62 1.74
Age 0 Top Concepts 0.02 0.20 0.02 0.17 0.04 0.03 0.22 0.02 0.20 0.03 0.02 0.19
Age ≤ 5 Top Concepts 0.33 0.94 0.23 0.77 0.12 0.27 0.84 0.19 0.71 0.10 0.22 0.76
Total Concepts 138.42 47.04 108.70 58.84 0.56 120.35 67.83 95.93 68.55 0.36 105.73 64.53
Total MeSH Descriptors 13.86 5.24 11.22 5.69 0.48 13.22 5.37 10.77 6.02 0.43 11.34 5.86
Total MeSH Qualifiers 9.01 5.80 6.84 5.21 0.39 8.68 5.93 6.64 5.42 0.36 7.03 5.45
Author Count 5.34 3.89 4.63 7.55 0.12 6.17 6.12 5.15 14.71 0.09 5.03 11.21
Corporate Author 0.00 0.01 0.01 0.08 -0.11 0.00 0.01 0.01 0.07 -0.10 0.00 0.07
Journal Article 0.99 0.12 0.91 0.29 0.36 0.98 0.15 0.91 0.28 0.28 0.92 0.27
Research Support, U.S. Gov’t, Non-P.H.S. 0.14 0.35 0.03 0.18 0.39 0.13 0.34 0.03 0.17 0.37 0.05 0.21
Research Support, ARRA 0.00 0.00 0.00 0.00 . 0.00 0.05 0.00 0.01 0.07 0.00 0.01
Research Support, Non-U.S. Gov’t 0.48 0.50 0.40 0.49 0.16 0.48 0.50 0.45 0.50 0.06 0.44 0.50
Review Article 0.11 0.32 0.11 0.32 -0.00 0.12 0.32 0.10 0.30 0.06 0.11 0.31
English Abstract 0.00 0.02 0.01 0.11 -0.14 0.00 0.02 0.01 0.09 -0.12 0.01 0.09
Case Report 0.01 0.09 0.07 0.26 -0.32 0.01 0.10 0.06 0.24 -0.28 0.06 0.23
Comparative Study 0.12 0.32 0.10 0.30 0.05 0.06 0.24 0.06 0.23 0.01 0.08 0.27
Meta-Analysis 0.00 0.05 0.00 0.06 -0.02 0.01 0.07 0.01 0.09 -0.03 0.01 0.07
Evaluation Studies 0.02 0.14 0.03 0.16 -0.04 0.01 0.11 0.02 0.14 -0.05 0.02 0.15
Guideline 0.00 0.02 0.00 0.04 -0.05 0.00 0.03 0.00 0.04 -0.02 0.00 0.04
Multicenter Study 0.02 0.13 0.02 0.12 0.02 0.02 0.14 0.02 0.13 0.04 0.02 0.13
Observational Study 0.00 0.00 0.00 0.00 -0.00 0.00 0.03 0.00 0.04 -0.01 0.00 0.03
Randomized Controlled Trial 0.03 0.16 0.03 0.16 -0.00 0.03 0.17 0.03 0.16 0.03 0.03 0.16
Technical Report 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 -0.00 0.00 0.01
Twin Study 0.00 0.05 0.00 0.02 0.05 0.00 0.04 0.00 0.02 0.05 0.00 0.03
Validation Studies 0.01 0.10 0.01 0.09 0.00 0.01 0.08 0.01 0.09 -0.00 0.01 0.09
Clinical Trial 0.03 0.16 0.03 0.17 -0.02 0.02 0.13 0.01 0.12 0.01 0.02 0.15
Irregular Article 0.02 0.14 0.11 0.32 -0.37 0.04 0.19 0.11 0.31 -0.28 0.10 0.30
Other Language 0.00 0.01 0.00 0.06 -0.08 0.00 0.01 0.00 0.05 -0.07 0.00 0.05
English 1.00 0.02 0.98 0.12 0.17 1.00 0.02 0.99 0.11 0.14 0.99 0.11
German 0.00 0.00 0.00 0.03 -0.04 0.00 0.00 0.00 0.03 -0.04 0.00 0.03
French 0.00 0.01 0.00 0.05 -0.07 0.00 0.01 0.00 0.05 -0.06 0.00 0.05
Russian 0.00 0.01 0.00 0.04 -0.05 0.00 0.01 0.00 0.03 -0.04 0.00 0.03
Japanese 0.00 0.00 0.00 0.02 -0.03 0.00 0.00 0.00 0.03 -0.04 0.00 0.02
Spanish 0.00 0.01 0.00 0.05 -0.06 0.00 0.01 0.00 0.06 -0.07 0.00 0.05
Italian 0.00 0.00 0.00 0.02 -0.03 0.00 0.00 0.00 0.01 -0.02 0.00 0.02
Chinese 0.00 0.01 0.00 0.07 -0.09 0.00 0.01 0.00 0.05 -0.07 0.00 0.05
Other Grant Count 0.07 0.37 0.03 0.23 0.15 0.17 0.88 0.07 0.43 0.15 0.06 0.42
Commercial Affiliation 0.01 0.10 0.03 0.16 -0.12 0.01 0.09 0.02 0.14 -0.10 0.02 0.14
Educational Affiliation 0.65 0.48 0.50 0.50 0.32 0.65 0.48 0.52 0.50 0.25 0.53 0.50
Eductional/Hospital Affiliation 0.16 0.37 0.16 0.36 0.02 0.15 0.36 0.16 0.37 -0.03 0.16 0.36
Government Affiliation 0.00 0.05 0.01 0.07 -0.05 0.00 0.05 0.01 0.07 -0.05 0.01 0.07
Hospital Affiliation 0.07 0.25 0.10 0.30 -0.11 0.07 0.26 0.09 0.28 -0.05 0.09 0.28
Military Affiliation 0.00 0.03 0.00 0.05 -0.04 0.00 0.03 0.00 0.04 -0.03 0.00 0.04
Organization Affiliation 0.09 0.29 0.11 0.31 -0.05 0.10 0.29 0.10 0.30 -0.02 0.10 0.30
Unkown Affiliation 0.02 0.13 0.11 0.31 -0.39 0.02 0.15 0.10 0.30 -0.32 0.09 0.29
Observations 448,326 2,714,446 508,475 3,078,109 6,749,356
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Table A1.3: Summary Statistics for the Full PRCA Sample.
NIH Pre Comp. Pre NIH Post Comp. Post All
Mean SD Mean SD Std. Diff. Mean SD Mean SD Std. Diff. Mean SD
Outcome Variables
2-Yr For. Cites 10.45 18.05 5.33 12.06 0.33 7.17 19.03 3.89 11.17 0.21 5.59 13.69
All-Yr For. Cites 35.25 68.80 18.06 45.05 0.30 10.12 27.59 5.56 16.48 0.20 14.48 40.25
2-Yr For. Cites (Indicator) 0.89 0.31 0.73 0.44 0.42 0.74 0.44 0.61 0.49 0.28 0.70 0.46
All-Yr For. Cites (Indicator) 0.94 0.24 0.83 0.37 0.33 0.75 0.43 0.63 0.48 0.26 0.76 0.43
2-Yr Forward Cites (Com. Enterprise) 0.21 0.80 0.14 0.73 0.09 0.11 0.58 0.07 0.50 0.06 0.12 0.65
2-Yr Forward Cites (Dev. Country) 0.21 0.81 0.18 0.76 0.03 0.07 0.67 0.08 1.03 -0.00 0.14 0.87
TA Journal (DOAJ) 0.97 0.18 0.96 0.19 0.03 0.90 0.30 0.88 0.32 0.05 0.93 0.26
TA Journal (PMC-OAS) 0.96 0.18 0.97 0.15 -0.07 0.87 0.30 0.88 0.30 -0.02 0.93 0.24
Covariates
Backward Cites 36.09 30.95 23.64 27.76 0.42 37.54 35.17 26.83 30.64 0.32 27.78 30.54
OA Backward Cites 0.52 1.41 0.36 1.16 0.12 1.35 2.71 1.01 2.32 0.13 0.73 1.93
Age 0 Top Concepts 0.02 0.20 0.02 0.17 0.04 0.03 0.22 0.02 0.21 0.02 0.02 0.19
Age ≤ 5 Top Concepts 0.33 0.94 0.25 0.81 0.10 0.27 0.85 0.24 0.80 0.04 0.26 0.82
Total Concepts 138.39 47.10 117.79 56.95 0.39 120.12 68.02 105.82 70.59 0.21 116.00 63.37
Total MeSH Descriptors 13.87 5.26 12.32 5.54 0.29 13.25 5.38 12.46 5.80 0.14 12.65 5.61
Total MeSH Qualifiers 9.02 5.82 7.65 5.41 0.24 8.68 5.94 7.87 5.76 0.14 8.00 5.66
Author Count 5.34 3.90 4.72 3.25 0.17 6.19 6.16 5.40 3.83 0.15 5.21 4.01
Corporate Author 0.00 0.01 0.01 0.08 -0.11 0.00 0.01 0.00 0.06 -0.08 0.00 0.06
Journal Article 0.99 0.12 0.94 0.24 0.25 0.98 0.15 0.95 0.22 0.15 0.95 0.21
Research Support, U.S. Gov’t, Non-P.H.S. 0.14 0.35 0.03 0.18 0.39 0.13 0.34 0.03 0.18 0.36 0.06 0.23
Research Support, ARRA 0.00 0.00 0.00 0.00 . 0.00 0.05 0.00 0.01 0.07 0.00 0.02
Research Support, Non-U.S. Gov’t 0.48 0.50 0.46 0.50 0.04 0.49 0.50 0.53 0.50 -0.09 0.49 0.50
Review Article 0.11 0.32 0.13 0.34 -0.05 0.12 0.33 0.12 0.33 -0.00 0.12 0.33
English Abstract 0.00 0.02 0.05 0.22 -0.33 0.00 0.02 0.04 0.19 -0.28 0.04 0.18
Case Report 0.01 0.10 0.04 0.19 -0.20 0.01 0.10 0.03 0.17 -0.15 0.03 0.17
Comparative Study 0.12 0.32 0.11 0.31 0.03 0.06 0.24 0.07 0.25 -0.03 0.09 0.28
Meta-Analysis 0.00 0.05 0.00 0.06 -0.01 0.01 0.07 0.01 0.09 -0.03 0.00 0.07
Evaluation Studies 0.02 0.14 0.03 0.16 -0.04 0.01 0.11 0.02 0.14 -0.05 0.02 0.15
Guideline 0.00 0.02 0.00 0.04 -0.04 0.00 0.03 0.00 0.04 -0.02 0.00 0.03
Multicenter Study 0.02 0.13 0.02 0.12 0.02 0.02 0.14 0.02 0.14 0.01 0.02 0.13
Observational Study 0.00 0.00 0.00 0.00 . 0.00 0.03 0.00 0.04 -0.02 0.00 0.03
Randomized Controlled Trial 0.03 0.16 0.02 0.15 0.01 0.03 0.17 0.03 0.17 0.02 0.03 0.16
Technical Report 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 -0.00 0.00 0.01
Twin Study 0.00 0.05 0.00 0.02 0.04 0.00 0.04 0.00 0.03 0.04 0.00 0.03
Validation Studies 0.01 0.10 0.01 0.10 -0.00 0.01 0.08 0.01 0.09 -0.01 0.01 0.09
Clinical Trial 0.03 0.16 0.03 0.17 -0.01 0.02 0.13 0.02 0.13 -0.01 0.02 0.15
Irregular Article 0.02 0.14 0.07 0.26 -0.26 0.04 0.19 0.07 0.25 -0.13 0.06 0.24
Other Language 0.00 0.01 0.01 0.11 -0.16 0.00 0.01 0.01 0.09 -0.13 0.01 0.09
English 1.00 0.02 0.93 0.25 0.37 1.00 0.02 0.95 0.21 0.31 0.96 0.21
German 0.00 0.01 0.01 0.09 -0.13 0.00 0.00 0.01 0.07 -0.11 0.01 0.07
French 0.00 0.01 0.01 0.09 -0.13 0.00 0.01 0.01 0.08 -0.11 0.01 0.08
Russian 0.00 0.01 0.01 0.08 -0.11 0.00 0.01 0.00 0.07 -0.09 0.00 0.07
Japanese 0.00 0.00 0.01 0.08 -0.12 0.00 0.00 0.00 0.07 -0.09 0.00 0.07
Spanish 0.00 0.01 0.01 0.08 -0.11 0.00 0.01 0.01 0.08 -0.10 0.00 0.07
Italian 0.00 0.00 0.00 0.04 -0.06 0.00 0.00 0.00 0.03 -0.04 0.00 0.03
Chinese 0.00 0.01 0.02 0.12 -0.18 0.00 0.01 0.01 0.11 -0.16 0.01 0.10
Other Grant Count 0.07 0.37 0.03 0.26 0.13 0.17 0.89 0.11 0.55 0.09 0.08 0.50
Commercial Affiliation 0.01 0.10 0.03 0.16 -0.13 0.01 0.09 0.02 0.14 -0.10 0.02 0.14
Educational Affiliation 0.65 0.48 0.51 0.50 0.28 0.65 0.48 0.53 0.50 0.23 0.55 0.50
Eductional/Hospital Affiliation 0.16 0.37 0.16 0.37 0.01 0.15 0.36 0.17 0.38 -0.06 0.16 0.37
Government Affiliation 0.00 0.05 0.01 0.07 -0.05 0.00 0.05 0.01 0.07 -0.05 0.00 0.07
Hospital Affiliation 0.07 0.25 0.09 0.29 -0.08 0.07 0.26 0.08 0.28 -0.04 0.08 0.28
Military Affiliation 0.00 0.03 0.00 0.04 -0.03 0.00 0.03 0.00 0.04 -0.03 0.00 0.04
Organization Affiliation 0.09 0.29 0.11 0.31 -0.07 0.10 0.29 0.11 0.31 -0.03 0.10 0.31
Unkown Affiliation 0.02 0.13 0.09 0.29 -0.33 0.02 0.15 0.08 0.27 -0.25 0.07 0.26
Observations 437,941 1,707,488 494,907 1,464,350 4,104,686
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Table A1.4: Summary Statistics for the 1-to-1 PRCA Sample.
NIH Pre Comp. Pre NIH Post Comp. Post All
Mean SD Mean SD Std. Diff. Mean SD Mean SD Std. Diff. Mean SD
Outcome Variables
2-Yr For. Cites 10.43 18.04 7.77 15.31 0.16 7.12 19.12 5.13 15.75 0.11 7.53 17.25
All-Yr For. Cites 35.27 68.95 26.13 56.03 0.15 10.04 27.66 7.22 22.25 0.11 19.07 48.28
2-Yr For. Cites (Indicator) 0.89 0.31 0.84 0.37 0.16 0.74 0.44 0.68 0.46 0.12 0.78 0.41
All-Yr For. Cites (Indicator) 0.94 0.24 0.91 0.29 0.11 0.75 0.43 0.70 0.46 0.11 0.82 0.39
2-Yr Forward Cites (Com. Enterprise) 0.21 0.80 0.19 0.85 0.02 0.11 0.58 0.09 0.57 0.02 0.15 0.71
2-Yr Forward Cites (Dev. Country) 0.21 0.82 0.23 0.81 -0.02 0.08 0.68 0.09 1.69 -0.01 0.15 1.09
TA Journal (DOAJ) 0.97 0.18 0.96 0.19 0.03 0.90 0.30 0.88 0.33 0.07 0.92 0.27
TA Journal (PMC-OAS) 0.96 0.18 0.97 0.17 -0.03 0.87 0.30 0.86 0.32 0.03 0.91 0.26
Covariates
Backward Cites 36.02 31.00 31.41 29.07 0.15 37.38 35.16 33.23 32.41 0.12 34.55 32.17
OA Backward Cites 0.52 1.41 0.48 1.36 0.03 1.35 2.73 1.27 2.53 0.03 0.93 2.17
Age 0 Top Concepts 0.02 0.20 0.02 0.19 0.01 0.03 0.22 0.03 0.23 -0.00 0.03 0.21
Age ≤ 5 Top Concepts 0.34 0.94 0.35 0.97 -0.01 0.27 0.85 0.30 0.90 -0.03 0.31 0.92
Total Concepts 138.34 47.20 140.09 51.48 -0.04 119.70 68.30 120.89 71.56 -0.02 129.24 61.82
Total MeSH Descriptors 13.87 5.26 14.65 5.48 -0.15 13.23 5.39 14.19 5.57 -0.18 13.97 5.45
Total MeSH Qualifiers 9.01 5.82 9.78 6.07 -0.13 8.65 5.94 9.58 6.26 -0.15 9.25 6.05
Author Count 5.34 3.90 5.25 3.33 0.03 6.19 6.19 5.87 4.00 0.06 5.68 4.55
Corporate Author 0.00 0.01 0.00 0.04 -0.05 0.00 0.01 0.00 0.04 -0.05 0.00 0.03
Journal Article 0.99 0.12 0.98 0.14 0.04 0.98 0.15 0.97 0.16 0.01 0.98 0.14
Research Support, U.S. Gov’t, Non-P.H.S. 0.14 0.35 0.04 0.20 0.36 0.13 0.34 0.03 0.18 0.36 0.09 0.28
Research Support, ARRA 0.00 0.00 0.00 0.00 . 0.00 0.05 0.00 0.01 0.07 0.00 0.03
Research Support, Non-U.S. Gov’t 0.48 0.50 0.60 0.49 -0.24 0.49 0.50 0.64 0.48 -0.31 0.55 0.50
Review Article 0.11 0.32 0.12 0.32 -0.01 0.12 0.33 0.12 0.32 0.01 0.12 0.32
English Abstract 0.00 0.02 0.03 0.18 -0.25 0.00 0.02 0.02 0.16 -0.22 0.01 0.12
Case Report 0.01 0.10 0.01 0.11 -0.03 0.01 0.10 0.01 0.12 -0.04 0.01 0.11
Comparative Study 0.12 0.32 0.13 0.33 -0.03 0.06 0.24 0.07 0.25 -0.04 0.09 0.29
Meta-Analysis 0.00 0.05 0.00 0.06 -0.01 0.01 0.07 0.01 0.09 -0.03 0.00 0.07
Evaluation Studies 0.02 0.14 0.03 0.16 -0.03 0.01 0.12 0.02 0.13 -0.03 0.02 0.14
Guideline 0.00 0.02 0.00 0.03 -0.02 0.00 0.03 0.00 0.03 -0.01 0.00 0.02
Multicenter Study 0.02 0.13 0.02 0.13 0.01 0.02 0.15 0.02 0.14 0.01 0.02 0.14
Observational Study 0.00 0.00 0.00 0.00 . 0.00 0.03 0.00 0.04 -0.01 0.00 0.02
Randomized Controlled Trial 0.03 0.16 0.02 0.15 0.01 0.03 0.17 0.03 0.17 0.01 0.03 0.16
Technical Report 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 -0.00 0.00 0.01
Twin Study 0.00 0.04 0.00 0.03 0.02 0.00 0.04 0.00 0.03 0.02 0.00 0.04
Validation Studies 0.01 0.10 0.01 0.10 -0.00 0.01 0.09 0.01 0.08 0.00 0.01 0.09
Clinical Trial 0.03 0.16 0.03 0.17 -0.01 0.02 0.13 0.02 0.13 -0.00 0.02 0.15
Irregular Article 0.02 0.14 0.03 0.17 -0.06 0.04 0.19 0.04 0.20 -0.01 0.03 0.18
Other Language 0.00 0.01 0.01 0.08 -0.11 0.00 0.01 0.00 0.07 -0.10 0.00 0.05
English 1.00 0.02 0.97 0.18 0.26 1.00 0.02 0.97 0.16 0.23 0.98 0.12
German 0.00 0.01 0.00 0.06 -0.08 0.00 0.00 0.00 0.05 -0.07 0.00 0.04
French 0.00 0.01 0.00 0.06 -0.09 0.00 0.01 0.00 0.06 -0.08 0.00 0.04
Russian 0.00 0.01 0.00 0.05 -0.07 0.00 0.01 0.00 0.05 -0.07 0.00 0.04
Japanese 0.00 0.00 0.00 0.06 -0.08 0.00 0.00 0.00 0.05 -0.07 0.00 0.04
Spanish 0.00 0.01 0.00 0.05 -0.07 0.00 0.01 0.00 0.05 -0.06 0.00 0.04
Italian 0.00 0.00 0.00 0.03 -0.04 0.00 0.00 0.00 0.02 -0.03 0.00 0.02
Chinese 0.00 0.01 0.01 0.11 -0.15 0.00 0.01 0.01 0.10 -0.13 0.01 0.07
Other Grant Count 0.07 0.36 0.05 0.32 0.07 0.17 0.87 0.15 0.66 0.03 0.11 0.61
Commercial Affiliation 0.01 0.10 0.03 0.16 -0.13 0.01 0.09 0.02 0.15 -0.10 0.02 0.13
Educational Affiliation 0.65 0.48 0.57 0.49 0.16 0.64 0.48 0.57 0.50 0.16 0.61 0.49
Eductional/Hospital Affiliation 0.16 0.37 0.15 0.36 0.02 0.15 0.36 0.17 0.37 -0.05 0.16 0.36
Government Affiliation 0.00 0.05 0.00 0.07 -0.04 0.00 0.05 0.01 0.07 -0.05 0.00 0.06
Hospital Affiliation 0.07 0.25 0.07 0.25 -0.01 0.07 0.26 0.07 0.26 0.02 0.07 0.26
Military Affiliation 0.00 0.03 0.00 0.04 -0.03 0.00 0.03 0.00 0.04 -0.03 0.00 0.03
Organization Affiliation 0.09 0.29 0.13 0.34 -0.13 0.09 0.29 0.12 0.32 -0.07 0.11 0.31
Unkown Affiliation 0.02 0.13 0.04 0.20 -0.14 0.02 0.15 0.05 0.22 -0.13 0.03 0.18
Observations 431,647 431,647 481,002 481,002 1,825,298
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Table A2.1 Covariates in TA Sample
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
NIH Article 1.005 (0.0328) 0.172 (0.0160) 0.780 (0.0316) 0.171 (0.0160) 0.667 (0.0281) 0.120 (0.0098) 0.291 (0.0219) 0.038 (0.0087)
Post 2008 -0.028 (0.0232) 0.030 (0.0139) -0.107 (0.0229) 0.015 (0.0142) -0.038 (0.0230) 0.023 (0.0137) -0.126 (0.0259) -0.043 (0.0148)
NIH × Post 2008 -0.022 (0.0191) -0.039 (0.0087) 0.023 (0.0189) -0.032 (0.0087) -0.069 (0.0182) -0.059 (0.0088) 0.036 (0.0202) -0.009 (0.0100)
Backward Cites 0.002 (0.0003) 0.002 (0.0003) 0.002 (0.0005) 0.003 (0.0003)
OA Backward Cites 0.011 (0.0024) 0.010 (0.0024) 0.005 (0.0018) 0.004 (0.0018)
Age 0 Top Concepts 0.083 (0.0259) 0.083 (0.0263) 0.111 (0.0082) 0.110 (0.0082)
Age 5 Top Concepts 0.136 (0.0031) 0.136 (0.0030) 0.128 (0.0023) 0.124 (0.0023)
Total Concepts 0.003 (0.0002) 0.003 (0.0002) 0.002 (0.0001) 0.002 (0.0001)
Total MeSH Descriptors 0.018 (0.0019) 0.018 (0.0020) 0.013 (0.0013) 0.011 (0.0012)
Total MeSH Qualifiers -0.001 (0.0010) -0.001 (0.0010) -0.002 (0.0007) -0.003 (0.0008)
Author Count 0.001 (0.0004) 0.001 (0.0004) 0.009 (0.0014) 0.009 (0.0016)
Corporate Author -10.452 (1.0133) -10.357 (1.0165) -23.093 (0.2386) -20.544 (0.5956)
Journal Article -0.005 (0.1021) -0.009 (0.1065) 0.006 (0.1314) -0.112 (0.1751)
Res. Supp. U.S. Govt., Non-PHS 0.018 (0.0083) 0.018 (0.0083) 0.011 (0.0064) 0.002 (0.0060)
Res. Supp. ARRA 0.153 (0.0998) 0.154 (0.0998) 0.114 (0.1188) 0.129 (0.1202)
Res. Supp., Non-U.S. Govt. 0.133 (0.0117) 0.133 (0.0120) 0.109 (0.0091) 0.089 (0.0081)
Review Article 0.683 (0.0219) 0.689 (0.0227) 0.682 (0.0284) 0.628 (0.0235)
English Abstract 0.402 (0.0820) -0.035 (0.1582) 0.458 (0.1003) 0.539 (0.1985)
Case Report -0.545 (0.0244) -0.555 (0.0276) -0.390 (0.0190) -0.296 (0.0213)
Comparative Study 0.033 (0.0051) 0.033 (0.0052) 0.028 (0.0054) 0.024 (0.0058)
Meta-Analysis 0.424 (0.0201) 0.423 (0.0200) 0.400 (0.0196) 0.386 (0.0256)
Evaluation Studies 0.005 (0.0094) 0.004 (0.0097) 0.003 (0.0092) 0.006 (0.0113)
Guidline 1.123 (0.0758) 1.138 (0.0770) 0.886 (0.1425) 0.754 (0.1624)
Multicenter Study 0.277 (0.0268) 0.278 (0.0272) 0.232 (0.0206) 0.209 (0.0222)
Observational Study -0.837 (0.4174) -0.870 (0.4598) -1.131 (0.4978) -0.345 (0.5115)
Randomized Controlled Trial 0.161 (0.0209) 0.163 (0.0213) 0.154 (0.0159) 0.122 (0.0158)
Technical Report -0.016 (0.0983) 0.014 (0.0987) 0.012 (0.1045) -0.142 (0.0989)
Twin Study -0.069 (0.0248) -0.070 (0.0249) -0.065 (0.0246) -0.075 (0.0307)
Validation Studies 0.010 (0.0112) 0.007 (0.0116) 0.004 (0.0125) -0.008 (0.0179)
Clincial Trial 0.164 (0.0142) 0.167 (0.0145) 0.166 (0.0176) 0.185 (0.0226)
Irregular Article -0.699 (0.0625) -0.712 (0.0636) -0.722 (0.0880) -0.816 (0.1180)
Other Language -0.195 (0.1022) -0.047 (0.1668) -0.314 (0.1150) -0.304 (0.1629)
English 1.029 (0.1254) 0.604 (0.2103) 1.003 (0.1476) 1.144 (0.2423)
German 0.006 (0.1112) -0.223 (0.2029) -0.204 (0.1291) -0.181 (0.1723)
French -0.295 (0.1230) -0.364 (0.2188) -0.511 (0.1230) -0.512 (0.1450)
Russion -0.234 (0.0990) -0.239 (0.0685) -0.494 (0.1446) -0.468 (0.2137)
Japanese -0.479 (0.1156) -0.714 (0.3051) -0.619 (0.1402) -0.778 (0.1945)
Spanish -0.137 (0.0838) -0.104 (0.1177) -0.224 (0.0988) -0.057 (0.2221)
Italian -0.474 (0.1414) -0.663 (0.1495) -0.452 (0.1253) -0.607 (0.1694)
Chinese -0.279 (0.1380) -0.227 (0.2291) -0.500 (0.1690) -0.458 (0.2078)
Grant Count, Non-NIH 0.030 (0.0046) 0.030 (0.0046) -0.009 (0.0070) -0.012 (0.0064)
Commercial Affiliation 0.165 (0.0271) 0.167 (0.0282) 0.134 (0.0196) 0.130 (0.0222)
Educational Affiliation 0.039 (0.0155) 0.038 (0.0164) -0.012 (0.0108) -0.054 (0.0132)
Educational/Hospital Affiliation 0.055 (0.0178) 0.054 (0.0188) 0.007 (0.0134) -0.026 (0.0145)
Government Affiliation 0.145 (0.0291) 0.147 (0.0304) 0.105 (0.0270) 0.049 (0.0317)
Hospital Affiliation 0.049 (0.0181) 0.051 (0.0191) 0.014 (0.0135) -0.014 (0.0145)
Military Affiliation 0.063 (0.0295) 0.062 (0.0305) 0.030 (0.0291) 0.038 (0.0411)
Organization Affiliation 0.118 (0.0189) 0.116 (0.0198) 0.067 (0.0152) 0.028 (0.0180)
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the PRCA
similarity score. The standard errors are in parentheses next to the point estimates, and are clustered at the journal level.
57
Table A2.2 Covariates in OA Sample
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
NIH Article 1.208 (0.1008) 0.157 (0.0191) 0.796 (0.0913) 0.147 (0.0177) 0.764 (0.0899) 0.107 (0.0146) 0.378 (0.0616) 0.041 (0.0201)
Post 2008 0.134 (0.2733) 0.023 (0.0894) -0.203 (0.2465) -0.064 (0.0825) 0.051 (0.2490) -0.054 (0.0780) -0.040 (0.1880) -0.142 (0.0566)
NIH × Post 2008 -0.183 (0.0982) -0.075 (0.0245) -0.044 (0.0999) -0.046 (0.0230) -0.266 (0.0826) -0.063 (0.0200) -0.141 (0.0562) -0.022 (0.0218)
Backward Cites 0.003 (0.0008) 0.002 (0.0007) 0.002 (0.0006) 0.003 (0.0012)
OA Backward Cites 0.009 (0.0031) 0.009 (0.0031) 0.010 (0.0029) 0.026 (0.0058)
Age 0 Top Concepts 0.059 (0.0179) 0.058 (0.0186) 0.059 (0.0185) 0.063 (0.0199)
Age 5 Top Concepts 0.134 (0.0054) 0.134 (0.0055) 0.127 (0.0054) 0.119 (0.0056)
Total Concepts 0.002 (0.0003) 0.002 (0.0003) 0.001 (0.0003) 0.001 (0.0003)
Total MeSH Descriptors 0.012 (0.0026) 0.011 (0.0025) 0.010 (0.0028) 0.009 (0.0029)
Total MeSH Qualifiers -0.005 (0.0061) -0.004 (0.0064) -0.007 (0.0067) -0.009 (0.0061)
Author Count 0.021 (0.0033) 0.021 (0.0034) 0.020 (0.0034) 0.018 (0.0031)
Corporate Author -19.650 (0.2180) -18.890 (0.2796) -18.602 (0.3236) -15.288 (0.4976)
Journal Article -0.161 (0.1882) -0.174 (0.2063) -0.043 (0.2046) 0.063 (0.1683)
Res. Supp. U.S. Govt., Non-PHS 0.034 (0.0139) 0.036 (0.0142) 0.037 (0.0140) 0.026 (0.0152)
Res. Supp. ARRA 0.253 (0.1959) 0.260 (0.1957) 0.254 (0.1977) 0.255 (0.2055)
Res. Supp., Non-U.S. Govt. 0.094 (0.0253) 0.095 (0.0265) 0.073 (0.0292) 0.060 (0.0269)
Review Article 0.571 (0.0507) 0.563 (0.0531) 0.562 (0.0577) 0.465 (0.0566)
English Abstract 0.601 (0.2165) 0.225 (0.1982) 0.791 (0.2755) 1.845 (0.7444)
Case Report -0.435 (0.0688) -0.429 (0.0906) -0.269 (0.1005) -0.083 (0.1095)
Comparative Study 0.047 (0.0155) 0.043 (0.0166) 0.037 (0.0172) 0.025 (0.0235)
Meta-Analysis 0.189 (0.0638) 0.181 (0.0656) 0.127 (0.0821) 0.051 (0.0950)
Evaluation Studies -0.087 (0.0532) -0.089 (0.0564) -0.106 (0.0719) -0.120 (0.0896)
Guidline 1.086 (0.1523) 1.155 (0.1640) 1.102 (0.2164) 0.725 (0.5181)
Multicenter Study 0.044 (0.0409) 0.043 (0.0440) 0.015 (0.0499) -0.021 (0.0613)
Observational Study -1.936 (1.1315) -20.406 (0.9033) -20.222 (1.0012)
Randomized Controlled Trial -0.030 (0.0370) -0.045 (0.0395) -0.029 (0.0423) -0.023 (0.0541)
Technical Report -0.477 (0.1726) -0.692 (0.1446) -0.005 (0.2605)
Twin Study 0.104 (0.1498) 0.102 (0.1519) -0.004 (0.2104) 0.080 (0.2358)
Validation Studies -0.074 (0.1109) -0.079 (0.1122) -0.114 (0.1168) -0.110 (0.1227)
Clincial Trial 0.104 (0.0354) 0.122 (0.0357) 0.130 (0.0422) 0.156 (0.0480)
Irregular Article -0.657 (0.1310) -0.702 (0.1369) -0.615 (0.1362) -0.463 (0.1303)
Other Language -0.118 (0.1079) -0.069 (0.0943) -0.170 (0.1005) -0.380 (0.1086)
English 1.384 (0.2410) 0.873 (0.1998) 1.517 (0.3018) 2.509 (0.7360)
German 0.100 (0.1903) -0.390 (0.3626) -0.878 (0.1870) 0.270 (0.1719)
French 0.003 (0.3557) 0.028 (0.4113) 0.697 (0.4777) 1.808 (0.1786)
Russion -18.088 (1.0288) 1.037 (0.7610) -18.674 (1.0699)
Japanese 0.133 (0.1377) 0.256 (0.1182) 0.241 (0.1435) 0.529 (0.1710)
Spanish -0.135 (0.2236) -0.692 (0.2952) -0.060 (0.3703) -0.178 (0.4457)
Italian -0.475 (0.1191) -0.242 (0.3134) -0.993 (0.6637)
Chinese -0.002 (0.0132) -0.001 (0.0134) -0.009 (0.0118) -0.008 (0.0119)
Grant Count, Non-NIH 0.099 (0.0422) 0.097 (0.0465) 0.065 (0.0401) 0.085 (0.0364)
Commercial Affiliation 0.019 (0.0375) 0.013 (0.0411) -0.028 (0.0357) -0.027 (0.0410)
Educational Affiliation 0.027 (0.0381) 0.026 (0.0422) -0.019 (0.0452) -0.009 (0.0465)
Educational/Hospital Affiliation 0.020 (0.0637) 0.024 (0.0684) -0.021 (0.0647) -0.039 (0.0927)
Government Affiliation 0.023 (0.0355) 0.033 (0.0396) -0.013 (0.0384) 0.019 (0.0422)
Hospital Affiliation 0.020 (0.0843) 0.030 (0.0854) -0.020 (0.1230) 0.070 (0.1284)
Military Affiliation 0.120 (0.0323) 0.113 (0.0353) 0.068 (0.0291) 0.061 (0.0364)
Organization Affiliation
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the PRCA
similarity score. The standard errors are in parentheses next to the point estimates, and are clustered at the journal level.
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Table A2.3 Covariates in Full Sample (DDD)
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
NIH Article 1.219 (0.1044) 0.175 (0.0208) 0.798 (0.0935) 0.159 (0.0194) 0.766 (0.0919) 0.117 (0.0146) 0.378 (0.0622) 0.070 (0.0233)
Post 2008 0.011 (0.1195) 0.028 (0.0294) -0.180 (0.1124) -0.017 (0.0280) 0.005 (0.1003) -0.021 (0.0273) -0.090 (0.0750) -0.071 (0.0261)
NIH × Post 2008 -0.193 (0.1067) -0.055 (0.0283) -0.046 (0.1009) -0.025 (0.0264) -0.271 (0.0863) -0.045 (0.0233) -0.141 (0.0569) -0.015 (0.0212)
TA 0.236 (0.1387) 0.000 (0.0000) 0.034 (0.1288) 0.000 (0.0000) 0.104 (0.1366) 0.000 (0.0000) 0.102 (0.1150) 0.000 (0.0000)
NIH × TA -0.214 (0.1094) -0.002 (0.0262) -0.018 (0.0987) 0.013 (0.0249) -0.099 (0.0960) 0.003 (0.0161) -0.087 (0.0660) -0.033 (0.0231)
TA × Post 2008 -0.036 (0.1164) 0.002 (0.0269) 0.073 (0.1099) 0.032 (0.0254) -0.043 (0.0977) 0.042 (0.0246) -0.036 (0.0735) 0.024 (0.0245)
NIH × TA × Post 2008 0.172 (0.1085) 0.016 (0.0297) 0.069 (0.1027) -0.008 (0.0279) 0.202 (0.0882) -0.015 (0.0247) 0.177 (0.0604) 0.005 (0.0232)
Backward Cites 0.002 (0.0003) 0.002 (0.0003) 0.002 (0.0005) 0.003 (0.0003)
OA Backward Cites 0.010 (0.0022) 0.010 (0.0022) 0.008 (0.0019) 0.008 (0.0021)
Age 0 Top Concepts 0.081 (0.0238) 0.081 (0.0242) 0.106 (0.0081) 0.105 (0.0084)
Age 5 Top Concepts 0.136 (0.0030) 0.136 (0.0028) 0.128 (0.0022) 0.124 (0.0022)
Total Concepts 0.003 (0.0002) 0.003 (0.0002) 0.002 (0.0001) 0.002 (0.0001)
Total MeSH Descriptors 0.018 (0.0018) 0.018 (0.0019) 0.013 (0.0012) 0.011 (0.0011)
Total MeSH Qualifiers -0.001 (0.0010) -0.001 (0.0010) -0.002 (0.0007) -0.004 (0.0008)
Author Count 0.001 (0.0004) 0.001 (0.0004) 0.009 (0.0014) 0.009 (0.0016)
Corporate Author -10.476 (1.0140) -10.376 (1.0167) -23.095 (0.2337) -20.502 (0.5802)
Journal Article -0.013 (0.0987) -0.016 (0.1032) 0.001 (0.1272) -0.112 (0.1713)
Res. Supp. U.S. Govt., Non-PHS 0.021 (0.0079) 0.021 (0.0079) 0.013 (0.0062) 0.005 (0.0058)
Res. Supp. ARRA 0.161 (0.0918) 0.163 (0.0918) 0.125 (0.1086) 0.143 (0.1096)
Res. Supp., Non-U.S. Govt. 0.133 (0.0115) 0.133 (0.0117) 0.108 (0.0090) 0.088 (0.0079)
Review Article 0.678 (0.0217) 0.684 (0.0225) 0.677 (0.0268) 0.620 (0.0228)
English Abstract 0.406 (0.0791) -0.031 (0.1484) 0.469 (0.0971) 0.568 (0.1968)
Case Report -0.541 (0.0240) -0.552 (0.0273) -0.387 (0.0188) -0.291 (0.0211)
Comparative Study 0.034 (0.0049) 0.034 (0.0051) 0.029 (0.0053) 0.024 (0.0057)
Meta-Analysis 0.416 (0.0197) 0.415 (0.0196) 0.389 (0.0191) 0.372 (0.0251)
Evaluation Studies -0.001 (0.0099) -0.002 (0.0104) -0.005 (0.0113) -0.003 (0.0139)
Guidline 1.123 (0.0742) 1.139 (0.0757) 0.892 (0.1372) 0.754 (0.1600)
Multicenter Study 0.275 (0.0268) 0.276 (0.0272) 0.229 (0.0208) 0.206 (0.0224)
Observational Study -0.886 (0.4021) -0.937 (0.4502) -1.138 (0.4953) -0.346 (0.5129)
Randomized Controlled Trial 0.156 (0.0209) 0.158 (0.0214) 0.149 (0.0161) 0.118 (0.0160)
Technical Report -0.021 (0.0979) 0.008 (0.0985) 0.012 (0.1047) -0.141 (0.0999)
Twin Study -0.060 (0.0254) -0.061 (0.0255) -0.062 (0.0258) -0.067 (0.0320)
Validation Studies 0.003 (0.0144) 0.000 (0.0148) -0.008 (0.0168) -0.021 (0.0216)
Clincial Trial 0.165 (0.0141) 0.168 (0.0143) 0.166 (0.0174) 0.186 (0.0223)
Irregular Article -0.700 (0.0608) -0.714 (0.0620) -0.720 (0.0861) -0.808 (0.1165)
Other Language -0.174 (0.0818) -0.059 (0.1188) -0.257 (0.0885) -0.373 (0.1116)
English 1.081 (0.1112) 0.616 (0.1813) 1.083 (0.1322) 1.172 (0.2276)
German 0.050 (0.0988) -0.225 (0.1755) -0.142 (0.1160) -0.181 (0.1555)
French -0.251 (0.1076) -0.349 (0.1909) -0.422 (0.1093) -0.470 (0.1374)
Russion -0.209 (0.0903) -0.237 (0.0615) -0.445 (0.1340) -0.472 (0.2076)
Japanese -0.431 (0.1029) -0.708 (0.2895) -0.552 (0.1262) -0.780 (0.1791)
Spanish -0.034 (0.0800) 0.024 (0.1061) -0.058 (0.0997) 0.106 (0.1874)
Italian -0.424 (0.1261) -0.662 (0.1358) -0.385 (0.1184) -0.552 (0.1578)
Chinese -0.249 (0.1226) -0.219 (0.2063) -0.428 (0.1531) -0.503 (0.1917)
Grant Count, Non-NIH 0.031 (0.0046) 0.031 (0.0046) -0.009 (0.0072) -0.012 (0.0066)
Commercial Affiliation 0.163 (0.0260) 0.165 (0.0271) 0.130 (0.0191) 0.126 (0.0214)
Educational Affiliation 0.038 (0.0149) 0.036 (0.0159) -0.013 (0.0104) -0.054 (0.0127)
Educational/Hospital Affiliation 0.053 (0.0171) 0.052 (0.0181) 0.006 (0.0130) -0.026 (0.0141)
Government Affiliation 0.137 (0.0278) 0.139 (0.0291) 0.096 (0.0256) 0.044 (0.0301)
Hospital Affiliation 0.047 (0.0173) 0.050 (0.0183) 0.013 (0.0131) -0.014 (0.0140)
Military Affiliation 0.065 (0.0279) 0.066 (0.0289) 0.031 (0.0284) 0.045 (0.0395)
Organization Affiliation 0.119 (0.0181) 0.117 (0.0190) 0.067 (0.0145) 0.030 (0.0171)
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the PRCA
similarity score. The standard errors are in parentheses next to the point estimates, and are clustered at the journal level.
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Table A3 Impacts of the PMC Mandate on 2-Year Forward Citations (Non-Clustered
Standard Errors)
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [10.421] [10.421] [10.453] [10.436]
NIH × Post 2008 -0.022*** -0.039*** 0.023*** -0.032*** -0.069*** -0.059*** 0.036*** -0.009***
(0.0057) (0.0009) (0.0057) (0.0009) (0.0062) (0.0010) (0.0082) (0.0012)
%∆ -2.1 -3.8 2.3 -3.2 -6.7 -5.7 3.7 -0.9
%∆ (Upper 95% CI) -1.0 -3.7 3.5 -3.0 -5.5 -5.5 5.3 -0.7
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [10.226] [10.226] [10.262] [10.262]
NIH × Post 2008 -0.183*** -0.075*** -0.044** -0.046*** -0.266*** -0.063*** -0.141*** -0.022***
(0.0186) (0.0040) (0.0189) (0.0040) (0.0202) (0.0043) (0.0243) (0.0052)
%∆ -16.7 -7.2 -4.3 -4.5 -23.4 -6.1 -13.2 -2.2
%∆ (Upper 95% CI) -13.6 -6.5 -0.7 -3.8 -20.3 -5.3 -8.9 -1.2
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [10.415] [10.415] [10.447] [10.430]
NIH × Post 2008 × TA 0.172*** 0.016*** 0.069*** -0.008* 0.202*** -0.015*** 0.177*** 0.005
(0.0194) (0.0041) (0.0197) (0.0041) (0.0212) (0.0044) (0.0256) (0.0053)
%∆ 18.7 1.6 7.1 -0.8 22.4 -1.5 19.4 0.5
%∆ (Upper 95% CI) 23.3 2.4 11.4 0.0 27.6 -0.7 25.5 1.6
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are Eicker-Huber-White. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1) and
100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A4.1. Impacts of the PMC Mandate on the Count of Forward Citations Ever
Received
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [35.230] [35.230] [35.326] [35.352]
NIH × Post 2008 0.007 -0.012 0.050** -0.010 -0.033 -0.046*** 0.034 -0.017*
(0.0204) (0.0089) (0.0202) (0.0089) (0.0202) (0.0087) (0.0217) (0.0097)
%∆ 0.7 -1.2 5.2 -0.9 -3.2 -4.5 3.5 -1.7
%∆ (Upper 95% CI) 4.8 0.5 9.4 0.8 0.7 -2.9 8.0 0.2
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [32.718] [32.718] [32.862] [32.985]
NIH × Post 2008 -0.152 -0.043* -0.014 -0.029 -0.245*** -0.053** -0.162*** -0.038
(0.1032) (0.0246) (0.1092) (0.0241) (0.0877) (0.0212) (0.0567) (0.0277)
%∆ -14.1 -4.2 -1.4 -2.8 -21.7 -5.1 -15.0 -3.7
%∆ (Upper 95% CI) 5.2 0.5 22.1 1.9 -7.1 -1.1 -5.0 1.6
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [35.147] [35.147] [35.246] [35.275]
NIH × Post 2008 × TA 0.170 0.011 0.066 -0.001 0.218** -0.011 0.196*** 0.017
(0.1139) (0.0311) (0.1125) (0.0305) (0.0936) (0.0286) (0.0616) (0.0298)
%∆ 18.6 1.1 6.9 -0.1 24.4 -1.1 21.7 1.7
%∆ (Upper 95% CI) 48.2 7.5 33.2 6.1 49.4 4.6 37.3 7.8
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A4.2. Impacts of the PMC Mandate on the Count of Forward Citations Ever
Received from Researchers at Commercial Enterprises
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [ 0.595] [ 0.595] [ 0.598] [ 0.600]
NIH × Post 2008 -0.010 -0.062*** 0.035 -0.061*** -0.037 -0.092*** 0.015 -0.059***
(0.0251) (0.0150) (0.0251) (0.0150) (0.0248) (0.0163) (0.0257) (0.0174)
%∆ -1.0 -6.0 3.6 -5.9 -3.6 -8.8 1.5 -5.8
%∆ (Upper 95% CI) 4.0 -3.2 8.8 -3.1 1.2 -5.8 6.8 -2.5
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [ 0.568] [ 0.568] [ 0.574] [ 0.577]
NIH × Post 2008 -0.249*** -0.136** -0.078 -0.124** -0.292*** -0.134** -0.224*** -0.140*
(0.0949) (0.0546) (0.1079) (0.0547) (0.0863) (0.0527) (0.0741) (0.0764)
%∆ -22.1 -12.7 -7.5 -11.7 -25.3 -12.5 -20.1 -13.0
%∆ (Upper 95% CI) -6.1 -2.8 14.3 -1.7 -11.5 -3.0 -7.6 1.0
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [ 0.594] [ 0.594] [ 0.597] [ 0.599]
NIH × Post 2008 × TA 0.241** 0.056 0.109 0.047 0.258*** 0.042 0.238*** 0.113
(0.1050) (0.0576) (0.1106) (0.0575) (0.0918) (0.0586) (0.0782) (0.0880)
%∆ 27.3 5.7 11.5 4.8 29.4 4.3 26.9 12.0
%∆ (Upper 95% CI) 56.4 18.4 38.5 17.3 54.9 17.0 47.9 33.1
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A4.3. Impacts of the PMC Mandate on the Count of Forward Citations Ever
Received from Researchers in Poor/Developing Countries
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [ 0.663] [ 0.663] [ 0.667] [ 0.671]
NIH × Post 2008 -0.151*** -0.040* -0.097*** -0.026 -0.149*** -0.057*** -0.046 0.010
(0.0282) (0.0204) (0.0285) (0.0207) (0.0276) (0.0200) (0.0394) (0.0356)
%∆ -14.0 -3.9 -9.2 -2.6 -13.8 -5.5 -4.5 1.0
%∆ (Upper 95% CI) -9.1 0.0 -4.0 1.5 -9.1 -1.7 3.1 8.3
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [ 0.829] [ 0.829] [ 0.836] [ 0.844]
NIH × Post 2008 -0.339*** -0.153*** -0.163** -0.110*** -0.400*** -0.131*** -0.269*** -0.083
(0.0733) (0.0411) (0.0789) (0.0388) (0.0760) (0.0378) (0.0698) (0.0535)
%∆ -28.7 -14.1 -15.0 -10.5 -33.0 -12.3 -23.6 -8.0
%∆ (Upper 95% CI) -17.7 -6.9 -0.8 -3.4 -22.2 -5.6 -12.4 2.2
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [ 0.668] [ 0.668] [ 0.673] [ 0.677]
NIH × Post 2008 × TA 0.209** 0.075 0.071 0.034 0.256*** 0.024 0.223*** 0.047
(0.0837) (0.0511) (0.0871) (0.0489) (0.0842) (0.0453) (0.0801) (0.0666)
%∆ 23.2 7.8 7.3 3.5 29.2 2.5 25.0 4.8
%∆ (Upper 95% CI) 45.2 19.1 27.3 13.9 52.4 12.0 46.2 19.4
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A5. Impacts of the PMC Mandate on the Probability of Receiving a 2-Year Forward
Citations
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [ 0.891] [ 0.891] [ 0.891] [ 0.891]
NIH × Post 2008 -0.057*** -0.023*** -0.022*** -0.012*** -0.051*** -0.024*** -0.007** -0.008***
(0.0058) (0.0023) (0.0051) (0.0022) (0.0041) (0.0017) (0.0033) (0.0015)
%∆ -5.5 -2.2 -2.2 -1.2 -5.0 -2.3 -0.7 -0.8
%∆ (Upper 95% CI) -4.4 -1.8 -1.2 -0.8 -4.2 -2.0 -0.0 -0.5
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [ 0.897] [ 0.897] [ 0.897] [ 0.897]
NIH × Post 2008 -0.098*** -0.069*** 0.003 -0.021* -0.137*** -0.049*** -0.065*** -0.021**
(0.0324) (0.0137) (0.0401) (0.0113) (0.0235) (0.0111) (0.0184) (0.0103)
%∆ -9.3 -6.7 0.3 -2.1 -12.8 -4.8 -6.3 -2.1
%∆ (Upper 95% CI) -3.4 -4.1 8.4 0.1 -8.7 -2.7 -2.8 -0.1
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [ 0.891] [ 0.891] [ 0.891] [ 0.891]
NIH × Post 2008 × TA 0.053 0.051*** -0.022 0.008 0.090*** 0.029** 0.058*** 0.014
(0.0387) (0.0148) (0.0412) (0.0122) (0.0255) (0.0116) (0.0186) (0.0106)
%∆ 5.4 5.3 -2.2 0.8 9.4 2.9 5.9 1.4
%∆ (Upper 95% CI) 13.7 8.4 6.0 3.3 15.0 5.3 9.9 3.6
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers next to “NIH × Post 2008” and “NIH ×
Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in square brackets are the
means, for the given sample, of the outcome variable for NIH articles prior to the mandate. The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A6. Impacts of the PMC Mandate on the Probability of Ever Receiving a Forward
Citation
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [ 0.937] [ 0.937] [ 0.937] [ 0.937]
NIH × Post 2008 0.043*** 0.070*** 0.047*** 0.054*** 0.008** 0.027*** 0.012*** 0.011***
(0.0054) (0.0026) (0.0048) (0.0024) (0.0034) (0.0017) (0.0028) (0.0015)
%∆ 4.4 7.2 4.8 5.6 0.8 2.7 1.2 1.1
%∆ (Upper 95% CI) 5.5 7.8 5.8 6.1 1.4 3.1 1.8 1.4
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [ 0.948] [ 0.948] [ 0.948] [ 0.948]
NIH × Post 2008 0.073** 0.053*** 0.090** 0.043*** -0.033** 0.012 -0.028** -0.001
(0.0293) (0.0111) (0.0404) (0.0128) (0.0148) (0.0078) (0.0117) (0.0078)
%∆ 7.6 5.5 9.4 4.4 -3.2 1.2 -2.7 -0.1
%∆ (Upper 95% CI) 14.0 7.8 18.4 7.0 -0.4 2.8 -0.5 1.5
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [ 0.938] [ 0.938] [ 0.938] [ 0.937]
NIH × Post 2008 × TA -0.027 0.016 -0.043 0.010 0.043*** 0.016** 0.040*** 0.012
(0.0323) (0.0116) (0.0403) (0.0131) (0.0158) (0.0079) (0.0119) (0.0082)
%∆ -2.7 1.6 -4.2 1.0 4.4 1.6 4.1 1.2
%∆ (Upper 95% CI) 3.7 4.0 3.7 3.6 7.7 3.2 6.5 2.8
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A7. Impacts of the PMC Mandate on 2-Year Forward Citations (OLS in Levels)
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [10.421] [10.421] [10.453] [10.436]
NIH × Post 2008 -0.168 -0.196** 0.034 -0.184* -0.416** -0.305*** 0.260 -0.100
(0.1663) (0.0967) (0.1674) (0.0968) (0.1641) (0.0840) (0.1900) (0.0835)
%∆ -1.6 -1.9 0.3 -1.8 -4.0 -2.9 2.5 -1.0
%∆ (Upper 95% CI) 1.5 -0.1 3.5 0.1 -0.9 -1.3 6.1 0.6
Observations 6,160,014 6,160,014 4,932,288 4,932,288 3,092,858 3,092,858 1,336,796 1,336,796
Panel B: OA Journals [10.226] [10.226] [10.262] [10.262]
NIH × Post 2008 -1.575*** -0.822*** -1.004* -0.710** -2.037*** -0.619** -1.377*** -0.220
(0.6031) (0.3128) (0.5984) (0.3043) (0.5821) (0.2562) (0.4910) (0.2424)
%∆ -15.4 -8.0 -9.8 -6.9 -19.8 -6.0 -13.4 -2.1
%∆ (Upper 95% CI) -3.8 -2.0 1.7 -1.1 -8.7 -1.1 -4.0 2.5
Observations 394,140 394,140 267,827 267,827 175,029 175,029 80,052 80,052
Panel C: Triple Diff [10.415] [10.415] [10.447] [10.430]
NIH × Post 2008 × TA 1.444** 0.398 1.049* 0.319 1.651*** 0.058 1.637*** -0.044
(0.6223) (0.3198) (0.6175) (0.3172) (0.6099) (0.2718) (0.5293) (0.2478)
%∆ 13.9 3.8 10.1 3.1 15.8 0.6 15.7 -0.4
%∆ (Upper 95% CI) 25.6 9.8 21.7 9.0 27.3 5.7 25.6 4.2
Observations 6,554,154 6,554,154 5,200,115 5,200,115 3,267,887 3,267,887 1,416,848 1,416,848
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes–The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed in
the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the OLS point estimates, δˆ, of δ in equations (1) and (2) specified as linear in levels. The
numbers in parentheses below are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI)
are computed relative to the mean of the outcome variable, y¯: 100 ∗ (δˆ/y¯) and 100 ∗ (ul/y¯). where ul = δˆ + 1.96 ∗ SE(δˆ) is the
upper limit of the 95% confidence interval for δ.
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Table A8. Impacts of the PMC Mandate on 2-Year Forward Citations (no Comparison
Articles Subject to non-NIH OA Mandate)
MEDLINE Journal Full PRCA 1-to-1 PRCA
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: TA Journals [10.421] [10.421] [10.453] [10.391]
NIH × Post 2008 0.010 -0.038*** 0.053*** -0.031*** -0.032 -0.055*** 0.060*** -0.004
(0.0201) (0.0090) (0.0198) (0.0090) (0.0193) (0.0086) (0.0210) (0.0100)
%∆ 1.0 -3.7 5.4 -3.0 -3.1 -5.4 6.2 -0.4
%∆ (Upper 95% CI) 5.1 -2.0 9.6 -1.3 0.6 -3.8 10.7 1.6
Observations 6,095,402 6,095,402 4,869,124 4,869,124 3,048,641 3,048,641 1,235,460 1,235,460
Panel B: OA Journals [10.226] [10.226] [10.262] [10.214]
NIH × Post 2008 -0.183* -0.075*** -0.044 -0.046** -0.266*** -0.063*** -0.144** -0.018
(0.0982) (0.0245) (0.0999) (0.0230) (0.0826) (0.0200) (0.0564) (0.0211)
%∆ -16.7 -7.2 -4.3 -4.5 -23.4 -6.1 -13.4 -1.8
%∆ (Upper 95% CI) 1.0 -2.6 16.4 -0.1 -9.9 -2.3 -3.3 2.3
Observations 394,140 394,140 267,827 267,827 175,029 175,029 78,618 78,618
Panel C: Triple Diff [10.415] [10.415] [10.447] [10.385]
NIH × Post 2008 × TA 0.205* 0.017 0.099 -0.007 0.240*** -0.012 0.208*** 0.005
(0.1092) (0.0298) (0.1033) (0.0281) (0.0887) (0.0246) (0.0608) (0.0225)
%∆ 22.7 1.7 10.4 -0.7 27.1 -1.2 23.2 0.5
%∆ (Upper 95% CI) 52.0 7.8 35.2 4.9 51.2 3.7 38.7 5.0
Observations 6,489,542 6,489,542 5,136,951 5,136,951 3,223,670 3,223,670 1,376,202 1,376,202
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The MEDLINE sample contains all NIH and comparison articles published between 2003 and 2011 that are indexed
in the 2016 baseline files. The Journal sample contains comparison articles published in the same journal-year as at least one
NIH article, the full PRCA sample contains comparison articles harvested using the PubMed Related Citations Algorithm
(PRCA), and the 1-to-1 PRCA sample contains comparison articles most similar to each NIH article on the basis of the
PRCA similarity score. The article-level covariates include backward citations, text-based metrics, MeSH term counts, author
counts, and sets of indicators for whether the author is a corporate entity, institution type, publication type, language, and
grant support. Also included are country and journal fixed effects. The numbers in square brackets are the means, for the
given sample, of the outcome variable for NIH articles prior to the mandate. The numbers next to “NIH × Post 2008” and
“NIH × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses below
are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as 100 ∗ (eδˆ − 1)
and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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Table A9. Impacts of the PMC Mandate on 2-Year Forward Citations (By Intramural and
Extramural Articles)
DID Toll Access DID Open Access Triple Diff DID All
(1) (2) (3) (4) (5) (6) (7) (8)
[13.290] [13.512] [13.303] [13.303]
NIH Intramural × Post 2008 0.001 -0.027 -0.019 -0.125** 0.019 0.084 -0.003 -0.031
(0.0244) (0.0211) (0.1110) (0.0535) (0.1201) (0.0630) (0.0244) (0.0202)
%∆ 0.1 -2.6 -1.8 -11.7 1.9 8.8 -0.3 -3.0
Observations 707,211 707,211 37,865 37,865 745,076 745,076 745,076 745,076
Year Fixed Effects Yes Yes Yes Yes Yes Yes Yes Yes
Controls Yes Yes Yes Yes
Notes – The sample contains all NIH articles published between 2003 and 2011 that are indexed in the 2016 baseline files. The
article-level covariates include backward citations, text-based metrics, MeSH term counts, author counts, and sets of
indicators for whether the author is a corporate entity, institution type, publication type, language, and grant support. Also
included are country and journal fixed effects. The numbers in square brackets are the means, for the given sample, of the
outcome variable for NIH articles prior to the mandate. The numbers next to “NIH Intramural × Post 2008” and “NIH
Intramural × Post 2008 × TA” are the PPML point estimates, δˆ, of δ in equations (1) and (2). The numbers in parentheses
below are the standard errors, which are clustered at the journal level. %∆ and %∆ (Upper 95% CI) are computed as
100 ∗ (eδˆ − 1) and 100 ∗ (eul − 1) where ul = δˆ + 1.96 ∗ SE(δˆ) is the upper limit of the 95% confidence interval for δ.
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